



(11) **EP 2 121 987 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
13.06.2012 Bulletin 2012/24

(21) Application number: **08729548.1**

(22) Date of filing: **11.02.2008**

(51) Int Cl.:
C12Q 1/68 (2006.01)

(86) International application number:
PCT/US2008/053603

(87) International publication number:
WO 2008/098248 (14.08.2008 Gazette 2008/33)

(54) **PARTICLES FOR DETECTING INTRACELLULAR TARGETS**

PARTIKEL ZUR ERKENNUNG INTRAZELLULÄRER ZIELE

PARTICULES UTILISÉES DANS LA DÉTECTION DE CIBLES INTRACELLULAIRES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: **09.02.2007 US 900648 P**
16.08.2007 US 956205 P

(43) Date of publication of application:
25.11.2009 Bulletin 2009/48

(73) Proprietor: **Northwestern University**
Evanston, IL 60208 (US)

(72) Inventors:
• **MIRKIN, Chad, A.**
Wilmette, IL 60091 (US)
• **SEFEROS, Dwight**
Toronto, Ontario, Canada M4Y 3GS (CA)
• **GILJOHANN, David, A.**
Chicago, IL 60626 (US)

(74) Representative: **Mallalieu, Catherine Louise et al**
D Young & Co LLP
120 Holborn
London EC1N 2DY (GB)

(56) References cited:
US-A1- 2006 183 247 US-A1- 2007 105 139

- **ZHANG CHUN-YANG ET AL: "Single-quantum-dot-based DNA nanosensor" NATURE MATERIALS, vol. 4, no. 11, November 2005 (2005-11), pages 826-831, XP002490176 ISSN: 1476-1122**

- **DUBERTRET B ET AL: "Single-mismatch detection using gold-quenched fluorescent oligonucleotides" NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 19, no. 4, 1 April 2001 (2001-04-01), pages 365-370, XP002224627 ISSN: 1087-0156**
- **MAXWELL D J ET AL: "SELF-ASSEMBLED NANOPARTICLE PROBES FOR RECOGNITION AND DETECTION OF BIOMOLECULES" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC.; US, US, vol. 124, no. 32, 14 August 2002 (2002-08-14), pages 9606-9612, XP001179600 ISSN: 0002-7863**
- **SEFEROS DWIGHT S ET AL: "Nano-flares: Probes for transfection and mRNA detection in living cells" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, no. 50, December 2007 (2007-12), pages 15477-15479, XP002490177 ISSN: 0002-7863**
- **ROSI N L ET AL: "Oligonucleotide-modified gold nanoparticles for intracellular gene regulation" SCIENCE, WASHINGTON, DC, vol. 312, no. 5776, 19 May 2006 (2006-05-19), pages 1027-1030, XP002403862 ISSN: 0036-8075 cited in the application**
- **DUBERTRET B ET AL: "In vivo imaging of quantum dots encapsulated in phospholipid micelles" SCIENCE, WASHINGTON, DC, vol. 298, no. 5599, 29 November 2002 (2002-11-29), pages 1759-1762, XP002255863 ISSN: 0036-8075**
- **PENN SHARRON G ET AL: "Nanoparticles for bioanalysis." CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 7, no. 5, October 2003 (2003-10), pages 609-615, XP002490178 ISSN: 1367-5931**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 121 987 B1

Description**GRANT FUNDING DISCLOSURE**

5 [0001] This invention was made with government support under grant numbers IU54-CA 119341, awarded by the Cancer Center for Nanotechnology Excellence (NCI/CCNE) and 5DPIOD000285, awarded from a NIH Director's Pioneer Award, and grant number EEC-0647560, awarded by the NSEC. The government has certain rights in the invention.

FIELD OF THE INVENTION

10 [0002] The present invention relates to methods of detecting the intracellular concentration of a target molecule using a nanoparticle wherein the nanoparticle comprises a binding moiety that can specifically associate with the target molecule, and wherein said association results in a change in a detectable marker that can be measured after association with the target molecule.

BACKGROUND OF THE INVENTION

15 [0003] Labeled oligonucleotides are widely used probes for detecting specific macromolecule targets such as nucleic acids and proteins. Their ability to bind targets with high specificity has rendered them useful in *in vitro* assays such as polymerase chain reaction (PCR) protocols. However, delivering these types of target specific probes into living cells remains a major challenge as cells are both naturally resistant to nucleic acid uptake and contain a variety of pathways to remove these foreign genetic materials. Thus, methods that deliver these materials into cells, in a manner in which they retain both their specific binding properties and fluorescent signaling ability are of great interest.

20 [0004] The discovery and subsequent development of the oligonucleotide-nanoparticle conjugate have lead to a variety of new opportunities in molecular diagnostics (Elghanian et al., 1997, Science 277: 1078-1081; Nam et al., 2003, Science 308: 1884-1886) and materials design (Mirkin et al., 1996, Nature 382: 607-609; Alivisatos et al., 1996, Nature 382: 609-611; Demers et al., 2003, Angew. Chem. Int. Ed. 40: 3071-3073). Recently, it has been demonstrated that oligonucleotide-functionalized nanoparticles enter cells and act as antisense agents to control gene expression (Rosi et al., 2006, Science 312: 1027-1030). These "antisense particles" are not simply delivery vehicles (Sandhu et al., 2002, Bioconjugate Chem. 13: 3-6; Tkachenko et al., 2003, J. Am. Chem. Soc. 125: 4700-4701), but rather single entity regulation and transfection agents that undergo cellular internalization, resist enzymatic degradation, and bind intracellular targets with affinity constants that are as much as two orders of magnitude greater than free oligonucleotides (Lytton-Jean and Mirkin, 2005, J. Am. Chem. Soc. 127: 12754-12755). Moreover, they can be easily modified with potent, *i.e.*, highly stable, designer materials such as locked nucleic acids (Seferos et al., 2007, ChemBioChem 8: 1230-1232) and are nontoxic under conditions required for gene regulation. Indeed, it has been shown that, unlike oligonucleotides free in solution, oligonucleotide-modified gold nanoparticles are readily taken up by cells in high numbers. This property has lead to the discovery that oligonucleotide-modified gold nanoparticles can be used as agents for intracellular gene control, where they provide rapid intracellular delivery of DNA, and further increase the efficacy of the oligonucleotides in the cells based on cooperative properties. These oligonucleotide functionalized nanoparticles have been shown to enter a variety of cell types, and can be used to introduce high local concentrations of oligonucleotides.

30 [0005] It has also previously been shown that gold nanoparticles that are densely functionalized with DNA bind complementary DNA in a highly cooperative manner, resulting in a binding strength that is two orders-of-magnitude greater than that determined for analogous DNA strands that are not attached to a gold nanoparticle. This property has rendered nanoparticles particularly useful for DNA and protein diagnostic assays in addition to those uses described above.

35 [0006] One class of oligonucleotides of interest are those that can detect a specific target with a recognition sequence. These types of structures, if introduced into living cells, are especially of interest for medical diagnosis, drug discovery, and developmental and molecular biology application. However, current delivery/transfection strategies lack the attributes required for their use such as 1) low toxicity, 2) high cellular uptake, and 3) provide resistance to enzymes that lead to false positive signals.

40 [0007] Probes to visualize and detect intracellular RNA including those used for *in situ* staining (Femino et al., Science 280: 585-590, 1998; Kloosterman et al., Nat. Methods 3: 27-29, 2006), molecular beacons (Tyagi et al., 1996, Nat. Biotechnol. 14: 303-308; Sokol et al., 1998, Proc. Natl. Acad. Sci. USA 95: 11538-11543; Peng et al., 2005, Cancer Res. 65: 1909-1917; Perlette et al., 2001, Anal.Chem. 73: 5544-5550; Nitin et al., 2004, Nucleic Acids Res. 32: e58), and FRET-pairs (Santangelo et al., 2004, Nucleic Acids Res. 32: e57; Bratu et al., 2003, Proc. Natl. Acad. Sci. USA 100: 13308-13313) each of which are important biological tools to measure and quantify activity in living systems in response to external stimuli (Santangelo et al., 2006, Annals of Biomedical Engineering 34: 39-50). However, the delivery of oligonucleotide-based reporters into cellular media and cells has proven to be a major challenge for intracellular detection. The cellular internalization of oligonucleotide-based probes typically requires transfection agents such as

lipids (Zabner et al., 1995, J. Bio. Chem. 270: 18997-19007) or dendrimers (Kukowska-Latallo et al., 1996, Proc. Natl. Acad. Sci. USA 93: 4897-4902) which can be toxic or alter cellular processes. Furthermore, oligonucleotides are prone to degradation within cells (Opalinska and Gewirtz, 2002, Nat. Rev. Drug Disc. 1: 503-514), and in the case of fluorophore-labeled probes, this can lead to a high background signal that is indistinguishable from a true recognition event (Li et al., 2004, Nucleic Acids Res. 28: e52; Rizzo et al., 2002, Molecular and Cellular Probes 16: 277-283).

[0008] Accordingly, while nanoparticle have been designed that can recognize targets with a high degree of specificity, it is difficult to detect a positive effect arising from the specific interaction, particularly with the sensitivity to detect such an interaction at the single cell level.

US 2006/183247 discloses (1) a method for detecting a specific binding for bio-molecules; (2) a method for detecting a presence of target molecules within a specimen; and (3) a method for measuring a quantity of target molecules existing in a specimen, in which a pair of energy donor and energy acceptor displaying a FRET phenomenon is used to guide a specific binding between a pair of bio-molecules.

Zhang et al. (Nature Materials 4, 826 - 831 (2005)) discloses a nanosensor based on fluorescence resonance energy transfer (FRET) capable of detecting low concentrations of DNA in a separation-free format.

Dubertret et al. (Nature Biotechnology 19, 365 - 370 (2001)) discloses single-mismatch detection using gold-quenched fluorescent oligonucleotides.

Maxwell et al. (J. Am. Chem. Soc., 2002, 124 (32), pp 9606-9612) discloses the use of colloidal gold nanocrystals to develop nanobiosensors that are able to recognize and detect specific DNA sequences and single-base mutations in a homogeneous format.

[0009] Thus there exists a need in the art to develop materials which are capable of entering a cell to associate with a specific target and methods to detect and quantitate the resulting intracellular interaction.

SUMMARY OF THE INVENTION

[0010] Provided here are methods of determining the intracellular concentration of a target molecule comprising the step of contacting the target molecule intracellularly with a nanoparticle under conditions that allow association of the target molecule with the nanoparticle, the nanoparticle comprising a binding moiety polynucleotide specific for said target molecule, the binding moiety polynucleotide labeled with a fluorescent marker, wherein the association of the target molecule and the

nanoparticle results in detectable change in the marker, and wherein the change in the detectable marker is proportional to the intracellular concentration of said target molecule.

[0011] We also describe methods in which the binding moiety is a polypeptide. In the embodiment wherein the binding moiety is a polynucleotide, alternative aspects include those in which the binding moiety is a DNA molecule or an RNA molecule. In other embodiments of the methods, the target molecule is a polynucleotide. In the embodiment wherein the target molecule is a polynucleotide, alternative aspects include those in which the binding moiety which is a DNA molecule or an RNA molecule.

[0012] In one embodiment, methods are provided wherein the binding moiety is a polynucleotide covalently attached to the nanoparticle and the marker is a fluorescent label attached to a polynucleotide hybridized to the binding moiety polynucleotide, wherein association of the binding moiety polynucleotide with the target molecule releases the hybridized polynucleotide and the marker is detectable after release. In one aspect, the marker is attached to the hybridized polynucleotide and the marker is quenched when the hybridized polynucleotide with the marker is hybridized to the binding moiety.

[0013] We also describe methods wherein the binding moiety is a polypeptide covalently attached to the nanoparticle and the marker is a label attached to an agent associated with the binding moiety polypeptide, wherein association of the binding moiety polypeptide with the target molecule displaces the associated agent and the marker is detectable after release. In one aspect, the marker is attached to the agent and the marker is quenched when the agent is associated with the binding moiety polypeptide.

[0014] In another embodiment, methods are provided wherein the polynucleotide binding moiety is labeled with a fluorescent market and the marker is detectable only when binding moiety is associated with the target molecule. Alternative aspects include those in which the binding moiety is a DNA molecule or an RNA molecule. In other embodiments of the methods, the target molecule is a polynucleotide. In the embodiment wherein the target molecule is a polynucleotide, alternative aspects include those in which the binding moiety which is a DNA molecule or an RNA molecule.

[0015] In one aspect, the fluorescent marker is attached to the polynucleotide binding moiety such that the marker is quenched when the polynucleotide binding moiety is not associated with the target molecule. Accordingly, the marker attached to the polynucleotide binding moiety is detectable only when the polynucleotide binding moiety is associated with the target molecule.

[0016] We also describe methods wherein the binding moiety is a polypeptide and the marker is attached to polypeptide binding moiety such that the marker is quenched when the polypeptide binding moiety is not associated with the target

molecule. Accordingly, the marker attached to the polypeptide binding moiety is detectable only when the polypeptide binding moiety is associated with the target molecule.

[0017] Also provided are methods wherein said nanoparticle comprises a multiplicity of binding moieties. In one aspect, methods are provided wherein the multiplicity of polynucleotide binding moieties specifically associate with one target molecule. In another aspect, the multiplicity of polynucleotide binding moieties specifically associate with more than one target molecule.

[0018] Further aspects of the invention will become apparent from the detailed description provided below. However, it should be understood that the following detailed description and examples, while indicating preferred embodiments of the invention, are given by way of illustration only

DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 provides a scheme for the gold nanoparticles modified with a fluorophore containing oligonucleotide that is capable of detecting an intracellular target.

[0020] Figure 2 shows nano-flares for mRNA detection and quantification.

[0021] Figure 3 describes quantification of survivin knockdown using nano-flares. (a) Flow cytometry data collected on siRNA treated SKBR3 cells. (b) Plot of mean fluorescence (black circles) and survivin expression (grey bar-graph) as a function of siRNA concentration.

DETAILED DESCRIPTION OF THE INVENTION

[0022] Methods provided herein exploit the physical properties and applications of nanoparticles modified to include one or more binding moieties that specifically recognize and associate with one or more specific target moieties. It is shown herein that intracellular concentrations of target molecules can be determined using nanoparticles that comprise a binding moiety that is specific for the target molecule. In the present invention the binding moiety polynucleotide is labeled with a fluorescent marker wherein the association of the target molecule and the nanoparticle results in detectable change in the marker, and wherein the change in the detectable marker is proportional to the intracellular concentration of said target molecule. It will be appreciated that the intracellular target includes those which are naturally occurring in the target cell, those which are naturally occurring targets that have been introduced into the cell (but are not ordinarily found in that cell type) or synthetic targets which do not occur in nature but have been introduced into the target cell.

[0023] In another aspect of the present invention, the intracellular localization of a desired target may also be determined using the methods outlined herein.

[0024] As used herein, the term "binding moiety" is understood to encompass a polynucleotide or a polypeptide, or any other fragment or segment of any of the preceding molecules that can associate with a target of interest. This term includes, but is not limited to, small molecules of interest. As is understood in the art, the term "small molecule" includes organic and inorganic compounds which are either naturally-occurring compounds, modifications of naturally-occurring compounds, or synthetic compounds.

[0025] The methods disclosed are particularly amenable to use of binding moieties which recognize and associate with intracellular target molecules, wherein the binding moieties are polynucleotides and/or polypeptides, and the target molecules are polynucleotides and/or polypeptides. In a simple aspect, a polynucleotide binding moiety specifically associates with a polynucleotide target molecule or a polypeptide binding moiety specifically associates with a polypeptide target molecule. However, methods are also contemplated wherein a polynucleotide binding moiety specifically associates with a polypeptide target molecule or a polypeptide binding moiety specifically associates with a polynucleotide target molecule.

[0026] As used herein, the term "specifically recognizes" or "specifically associates" means that the binding moiety can identify and/or interact with one target molecule with a higher affinity and/or avidity compared to all other target molecules.

[0027] The methods described function under the principle that the binding moiety is directly or indirectly labeled with a marker, and association of the binding moiety with the target molecule results in the marker becoming detectable, or more detectable. Accordingly, when the binding moiety is not associated with the target molecule, the marker is relatively undetectable, or quenched. While it is understood in the art that the term "quench" or "quenching" is often associated with fluorescent markers, it is disclosed herein that the signal of any marker that is quenched when it is relatively undetectable. Thus, it is described herein that any marker which can be quenched can be substituted for the fluorescent marker.

[0028] In one aspect, the marker is a label attached directly to the binding moiety, and in another aspect, the marker is a label attached to an agent associated with the binding moiety, this agent having a lower binding affinity or binding avidity for the binding moiety such that association of the target molecule with the binding moiety causes the agent to be displaced from its association with the binding moiety.

5 [0029] When the marker is attached directly to the binding moiety, the marker is positioned such that it is relatively undetectable or quenched when the binding moiety is not associated with a target molecule. For example, with a polynucleotide binding moiety that is not associated with a target molecule, the marker can be positioned in proximity to the nanoparticle itself through either secondary structure which forms within the polynucleotide binding moiety, or the marker can be freely wavering in the aqueous environment such that at any given time the marker can be in proximity to the nanoparticle and its signal quenched or freely wavering (though still tethered to the nanoparticle) in the aqueous environment at a distance from the nanoparticle that the signal is not quenched. In this embodiment wherein no secondary structure holds the marker in a quenched position in proximity to the nanoparticle when the polynucleotide binding moiety is not in association with a target molecule, a level of background signal will necessarily be detected, and association of the polynucleotide binding moiety with a target molecule will strengthen the signal over background as a result of the fact that more marker will be displaced from sufficient proximity to the nanoparticle to impart a quenching effect.

10 [0030] Similarly when the binding moiety is a polypeptide, the marker on the binding moiety may be positioned such that a conformation change that occurs when the polypeptide binding moiety is in association with a target molecule results in the marker moving sufficiently away from the nanoparticle that its signal is relatively unquenched.

15 [0031] In aspects of the methods wherein the marker is indirectly associated with the binding moiety, association of the binding moiety with a target molecule cause a physical release of the marker such that the nanoparticle is no longer able to exert a quenching effect on the marker. For example, with a polynucleotide binding moiety, the marker may be labeled on a second polynucleotide which can hybridize to the polynucleotide binding moiety in a position such that the marker is in sufficient proximity to the nanoparticle that the nanoparticle exerts its quenching effect. When the polynucleotide binding molecule recognizes and associates with a target molecule, the hybridized and labeled polynucleotide is displaced, and the quenching effect of the nanoparticle is abated.

20 [0032] Thus, in one embodiment for example, methods are provided wherein gold nanoparticle modified to include a polynucleotide binding moiety which in turn is hybridized to complementary polynucleotide labeled with a fluorophore marker can be used as both transfection agents and cellular "nano-flares" for visualizing and quantifying RNA in living cells. Nano-flares take advantage of the highly efficient fluorescence quenching properties of gold (Dubertret et al., 2001, Nat. Biotechnol. 19: 365-370), cellular uptake of oligonucleotide nanoparticle conjugates without the use of transfection agents, and the enzymatic stability of such conjugates (Rosi et al., 2006, Science 312: 1027-1030), thus overcoming many of the challenges to creating sensitive and effective intracellular probes. Specifically, nano-flares exhibit high signaling, have low background fluorescence, and are sensitive to changes in the number of RNA transcripts present in cells. Thus, the nano-flares described herein are oligonucleotide functionalized nanoparticle conjugates designed to provide an intracellular fluorescence signal that directly or indirectly correlates with the relative amount of a specific intracellular RNA. RNA contemplated for detection in the disclosed methods include, but are not limited to, mRNA and hnRNA.

25 [0033] A similar mechanism operates for a polypeptide binding moiety, wherein an agent labeled with a marker and the agent is able to associate with the polypeptide binding moiety in such a way that its association brings the agent and marker sufficiently close to the nanoparticle that the marker is relatively quenched. When the polypeptide binding moiety associates with a specific target molecule, the agent is released or displaced as with the nano-flare described above and the quenching effect of the nanoparticle is relieved.

30 [0034] Regardless of the specific nature of the binding moiety, by utilizing nanoparticles densely functionalized with fluorophore-labeled oligonucleotides or polypeptides, several difficulties commonly associated with intracellular molecule detection are alleviated. These binding moieties do not require microinjection or auxiliary transfection reagents to enter cells, are highly resistant towards enzymatic degradation and are non-toxic under the conditions studied.

45 POLYNUCLEOTIDES

[0035] As used herein, the term "polynucleotide," either functionalized on a nanoparticle or as a target molecule, is used interchangeably with the term oligonucleotide.

50 [0036] The term "nucleotide" or its plural as used herein is interchangeable with modified forms as discussed herein and otherwise known in the art. In certain instances, the art uses the term "nucleobase" which embraces naturally-occurring nucleotides as well as modifications of nucleotides that can be polymerized.

[0037] Methods of making polynucleotides of a predetermined sequence are well-known in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed. 1989) and F. Eckstein (ed.) Oligonucleotides and Analogues, 1st Ed. (Oxford University Press, New York, 1991). Solid-phase synthesis methods are preferred for both oligoribonucleotides and oligodeoxyribonucleotides (the well-known methods of synthesizing DNA are also useful for synthesizing RNA). Oligoribonucleotides and oligodeoxyribonucleotides can also be prepared enzymatically.

55 [0038] In various aspects, methods provided include use of polynucleotides which are DNA oligonucleotides, RNA oligonucleotides, or combinations of the two types. Modified forms of oligonucleotides are also contemplated which include those having at least one modified internucleotide linkage. Modified polynucleotides or oligonucleotides are

described in detail herein below.

MODIFIED OLIGONUCLEOTIDES

5 **[0039]** Specific examples of oligonucleotides include those containing modified backbones or non-natural internucleoside linkages. Oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. Modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone are considered to be within the meaning of "oligonucleotide."

10 **[0040]** Modified oligonucleotide backbones containing a phosphorus atom include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Also contemplated are oligonucleotides having inverted polarity comprising a single 3' to 3' linkage at the 3'-most internucleotide linkage, i.e. a single inverted nucleoside residue which may be abasic (the nucleotide is missing or has a hydroxyl group in place thereof). Salts, mixed salts and free acid forms are also contemplated. Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 20 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050.

25 **[0041]** Modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages; siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts. See, for example., U.S. Patent Nos. 5,034,506; 30 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439.

35 **[0042]** In still other embodiments, oligonucleotide mimetics wherein both one or more sugar and/or one or more internucleotide linkage of the nucleotide units are replaced with "non-naturally occurring" groups. In one aspect, this embodiment contemplates a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone. See, for example US Patent Nos. 5,539,082; 5,714,331; and 5,719,262, and Nielsen et al., 1991, Science, 254: 1497-1500.

40 **[0043]** In still other embodiments, oligonucleotides are provided with phosphorothioate backbones and oligonucleotides with heteroatom backbones, and including -CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂-, -CH₂-O-N(CH₃)-CH₂-, -CH₂-N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- described in US Patent Nos. 5,489,677, and 5,602,240. Also contemplated are oligonucleotides with morpholino backbone structures described in US Patent No. 5,034,506.

45 **[0044]** In various forms, the linkage between two successive monomers in the oligo consists of 2 to 4, desirably 3, groups/atoms selected from -CH₂-, -O-, -S-, -NR^H-, >C=O, >C=NR^H, >C=S, -Si(R["])₂-, -SO-, -S(O)₂-, -P(O)₂-, -PO(BH₃)-, -P(O,S)-, -P(S)₂-, -PO(R["])-, -PO(OCH₃)-, and -PO(NHR^H)-, where RH is selected from hydrogen and C₁₋₄-alkyl, and R["] is selected from C₁₋₆-alkyl and phenyl. Illustrative examples of such linkages are -CH₂-CH₂-CH₂-, -CH₂O-CH₂-, -CH₂-CHOH-CH₂-, -O-CH₂-O-, -O-CH₂-CH₂-, -O-CH₂-CH=(including R⁵ when used as a linkage to a succeeding monomer), -CH₂-CH₂-O-, -NR^H-CH₂-CH₂-, -CH₂-CH₂-NR^H-, -CH₂-NR^H-CH₂-, -O-CH₂-CH₂-NR^H-, -NR^H-CO-O-, -NR^H-CO-NR^H-, -NR^H-CS-NR^H-, -NR^H-C(=NR^H)-NR^H-, -NR^H-CO-CH₂-NR^H-O-CO-O-, -O-O-CH₂-O-, -O-CH₂-CO-O-, -CH₂-CO-NR^H-, -O-CO-NR^H-, -NR^H-CO-CH₂-, -O-CH₂-CO-NR^H-, -O-CH₂-CH₂-NR^H-, -CH=N-O-, -CH₂-NR^H-O-, -CH₂-O-N=(including R⁵ when used as a linkage to a succeeding monomer), -CH₂-O-NR^H-, -CO-NR^H-CH₂-, -CH₂-NR^H-O-, -CH₂-NR^H-CO-, -O-NR^H-CH₂-, -O-NR^H-, -O-CH₂-S-, -S-CH₂-O-, -CH₂-CH₂-S-, -O-CH₂-CH₂-S-, -S-CH₂-CH=(including R⁵ when used as a linkage to a succeeding monomer), -S-CH₂-CH₂-, -S-CH₂-CH₂-O-, -S-CH₂-CH₂-S-, -CH₂-S-CH₂-, -CH₂-SO-CH₂-, -CH₂-SO₂-CH₂-, -O-SO-O-, -O-S(O)₂-O-, -O-S(O)₂-CH₂-, -O-S(O)₂-NR^H-, -NR^H-S(O)₂-CH₂-, -O-S(O)₂-CH₂-, -O-P(O)₂-O-, -O-P(O,S)-O-, -O-P(S)₂-O-, -S-P(O)₂-O-, -S-P(O,S)-O-, -S-P(S)₂-O-, -O-P(O)₂-S-, -O-P(O,S)-S-, -O-P(S)₂-S-, -S-P(O)₂-S-, -S-P(O,S)-S-, -S-P(S)₂-S-, -O-PO(R["])-O-, -O-PO(OCH₃)-O-, -O-PO(OCH₂CH₃)-O-, -O-PO(OCH₂CH₂S-R)-O-, -O-PO(BH₃)-O-, -O-PO(NHR^N)-O-, -O-P(O)=NR^H-, -NR^H-P(O)₂-O-, -O-P(O,NR^H)-O-, -CH₂-P(O)₂-O-, -O-P(O)₂-CH₂-, and -O-Si(R["])₂-O-; among which -CH₂-CO-NR^H-, -CH₂-NR^H-O-, -S-CH₂-O-, -O-P(O)₂-O-O-P(O,S)-O-, -O-P(S)₂-O-, -NR^H-P(O)₂-O-, -O-P(O,NR^H)-O-, -O-PO(R["])-O-, -O-PO(CH₃)-O-, and -O-PO

(NHR^N)-O-, where RH is selected from hydrogen and C₁₋₄-alkyl, and Rⁿ is selected from C₁₋₆-alkyl and phenyl, are contemplated. Further illustrative examples are given in Mesmaeker et. al, 1995, Current Opinion in Structural Biology, 5: 343-355 and Susan M. Freier and Karl-Heinz Altmann, 1997, Nucleic Acids Research, vol 25: pp 4429-4443.

[0045] Still other modified forms of oligonucleotides are described in detail in U.S. patent application NO. 20040219565.

[0046] Modified oligonucleotides may also contain one or more substituted sugar moieties. In certain aspects, oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Other embodiments include O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. In one aspect, a modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOB) (Martin et al., 1995, Helv. Chim. Acta, 78: 486-504) *i.e.*, an alkoxyalkoxy group. Other modifications include 2'-dimethylaminooxyethoxy, *i.e.*, a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples herein below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-DMAOE-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), *i.e.*, 2'-O-CH₂-O-CH₂-N(CH₃)₂, also described in examples herein below.

[0047] Still other modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂-CH=CH₂), 2'-O-allyl (2'-O-CH₂-CH=CH₂) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. In one aspect, a 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, for example, at the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. See, for example, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920.

[0048] In one aspect, a modification of the sugar includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring, thereby forming a bicyclic sugar moiety. The linkage is in certain aspects is a methylene C-(CH₂)_n group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

[0049] Oligonucleotides may also include base modifications or substitutions. As used herein, "unmodified" or "natural" bases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified bases include other synthetic and natural bases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified bases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (*e.g.* 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified bases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further bases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., 1991, Angewandte Chemie, International Edition, 30: 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., ed., CRC Press, 1993. Certain of these bases are useful for increasing the binding affinity and include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C. and are, in certain aspects combined with 2'-O-methoxyethyl sugar modifications. See, U.S. Pat. Nos. 3,687,808, U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; 5,750,692 and 5,681,941.

[0050] A "modified base" or other similar term refers to a composition which can pair with a natural base (*e.g.*, adenine,

guanine, cytosine, uracil, and/or thymine) and/or can pair with a non-naturally occurring base. In certain aspects, the modified base provides a T_m differential of 15, 12, 10, 8, 6, 4, or 2°C. or less. Exemplary modified bases are described in EP 1 072 679 and WO 97/12896.

[0051] By "nucleobase" is meant the naturally occurring nucleobases adenine (A), guanine (G), cytosine (C), thymine (T) and uracil (U) as well as non-naturally occurring nucleobases such as xanthine, diaminopurine, 8-oxo-N⁶-methyladenine, 7-deazaxanthine, 7-deazaguanine, N⁴,N⁴-ethanocytosin, N',N'-ethano-2,6-diaminopurine, 5-methylcytosine (mC), 5-(C³-C⁶-alkynyl-cytosine, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridin, isocytosine, isoguanine, inosine and the "non-naturally occurring" nucleobases described in Benner et al., U.S. Pat. No. 5,432,272 and Susan M. Freier and Karl-Heinz Altmann, 1997, Nucleic Acids Research, vol. 25: pp 4429-4443. The term "nucleobase" thus includes not only the known purine and pyrimidine heterocycles, but also heterocyclic analogues and tautomers thereof. Further naturally and non-naturally occurring nucleobases include those disclosed in U.S. Pat. No. 3,687,808 (Merigan, et al.), in Chapter 15 by Sanghvi, in Antisense Research and Application, Ed. S. T. Crooke and B. Lebleu, CRC Press, 1993, in Englisch et al., 1991, Angewandte Chemie, International Edition, 30: 613-722 (see especially pages 622 and 623, and in the Concise Encyclopedia of Polymer Science and Engineering, J. I. Kroschwitz Ed., John Wiley & Sons, 1990, pages 858-859, Cook, AntiCancer Drug Design 1991, 6, 585-607.

The term "nucleosidic base" or "base unit" is further intended to include compounds such as heterocyclic compounds that can serve like nucleobases including certain "universal bases" that are not nucleosidic bases in the most classical sense but serve as nucleosidic bases. Especially mentioned as universal bases are 3-nitropyrrole, optionally substituted indoles (e.g., 5-nitroindole), and optionally substituted hypoxanthine. Other desirable universal bases include, pyrrole, diazole or triazole derivatives, including those universal bases known in the art.

POLYPEPTIDES

[0052] As used herein, the term "polypeptide" refers to peptides, proteins, polymers of amino acids, hormones, viruses, and antibodies that are naturally derived, synthetically produced, or recombinantly produced. Polypeptides also include lipoproteins and post translationally modified proteins, such as, for example, glycosylated proteins, as well as proteins or protein substances that have D-amino acids, modified, derivatized, or non-naturally occurring amino acids in the D- or L- configuration and/or peptomimetic units as part of their structure.

[0053] Peptides contemplated for use in the methods described include those derived from commercially available sources. Libraries include structured peptide libraries comprising small, disulfide-constrained cyclic peptide compounds that range in size from six to twelve amino acids, wherein the number of distinct peptide structures in each library typically exceeds 1 billion; (ii) linear peptide libraries wherein 19 amino acids (no cysteine) at each position in a 20-mer peptide are allowed to create a library of 10 billion peptides; (iii) substrate phage peptide libraries wherein all 19 amino acids (no cysteine) at each position in a 13-mer peptide are allowed to create a library of approximately 100 million peptides.

[0054] Commercially available peptide libraries include those from Peptide libraries Eurogentec s.a. (Belgium), Dyax Corp. (Cambridge, MA) and Cambridge Peptide (Cambridge, UK).

[0055] Preparation of peptide libraries useful in practice of the method is well known in the art, as described by Jung (ed) Combinatorial Peptide and Nonpeptide Libraries: A Handbook and in Devlin et al., 1990, Science, Vol 249, Issue 4967: 404-406, as well from use of commercially available synthesis kits from, for example, Sigma-Genosys.

[0056] Proteins contemplated for use in the methods described include those derived from synthesized proteins libraries as described in Matsuura, et al., 2002, Protein Science 11: 2631-2643, Ohuchi et al., 1998, Nucleic Acids Res. October 1; 26(19): 4339-4346, WO/1999/011655, WO/1998/047343, US Patent No. 6844161 and US Patent No. 6403312. Commercially available kits for production of protein libraries are also known in the art and available from, for example, BioCat GmbH (Heidelberg).

[0057] Protein libraries useful in practice of the methods described are also commercially available from, for example, Dyax Corp. (Cambridge, MA).

DETECTABLE MARKER/LABEL

[0058] A "marker" as used herein is interchangeable with "label" and regardless of the type of interacting compound being identified, methods are described wherein polynucleotide or polypeptide complex formation is detected by an observable change. Complex formation may give rise to a color change which is observed with the naked eye or spectroscopically. When using gold nanoparticles, a red-to-blue color change occurs with nanoparticle aggregation which often is detected with the naked eye. In the present disclosure, aggregation is contemplated to occur as a result of separate nanoparticles, each containing binding moieties to a specific but different portion of the target molecule, bind the same target molecule.

[0059] Polynucleotide or polypeptide complex formation may give rise to aggregate formation which is observed by electron microscopy or by nephelometry. Aggregation of nanoparticles in general gives rise to decreased plasmon

resonance. Complex formation also gives rise to precipitation of aggregated nanoparticles which is observed with the naked eye or microscopically.

[0060] The observation of a color change with the naked eye may be made against a background of a contrasting color. For instance, when gold nanoparticles are used, the observation of a color change is facilitated by spotting a sample of the hybridization solution on a solid white surface (such as, without limitation, silica or alumina TLC plates, filter paper, cellulose nitrate membranes, nylon membranes, or a C-18 silica TLC plate) and allowing the spot to dry. Initially, the spot retains the color of the hybridization solution, which ranges from pink/red, in the absence of hybridization, to purplish-red/purple, if there has been hybridization. On drying at room temperature or 80° C. (temperature is not critical), a blue spot develops if the nanoparticle-oligonucleotide conjugates had been linked by hybridization prior to spotting. In the absence of hybridization, the spot is pink. The blue and the pink spots are stable and do not change on subsequent cooling or heating or over time providing a convenient permanent record of the test. No other steps (such as a separation of hybridized and unhybridized nanoparticle-oligonucleotide conjugates) are necessary to observe the color change.

[0061] An alternate method for visualizing the results from practice of the methods described is to spot a sample of nanoparticle probes on a glass fiber filter (*e.g.*, Borosilicate Microfiber Filter, 0.7 micron pore size, grade FG75, for use with gold nanoparticles 13 nm in size), while drawing the liquid through the filter. Subsequent rinsing washes the excess, non-hybridized probes through the filter, leaving behind an observable spot comprising the aggregates generated by hybridization of the nanoparticle probes (retained because these aggregates are larger than the pores of the filter). This technique allows for greater sensitivity, since an excess of nanoparticle probes can be used.

[0062] It will be understood that a marker will include any of the fluorophores described herein as well as other detectable markers known in the art. For example, markers described also include, but are not limited to, redox active probes, other nanoparticles, and quantum dots, as well as any marker which can be detected using spectroscopic means, *i.e.*, those markers detectable using microscopy and cytometry.

METHODS OF LABELING OLIGONUCLEOTIDES

[0063] Methods of labeling oligonucleotides with fluorescent molecules and measuring fluorescence are well known in the art. Suitable fluorescent molecules are also well known in the art and include without limitation 1,8-ANS (1-Anilinonaphthalene-8-sulfonic acid), 1-Anilinonaphthalene-8-sulfonic acid (1,8-ANS), 5-(and-6)-Carboxy-2', 7'-dichlorofluorescein pH 9.0, 5-FAM pH 9.0, 5-ROX (5-Carboxy-X-rhodamine, triethylammonium salt), 5-ROX pH 7.0, 5-TAMRA, 5-TAMRA pH 7.0, 5-TAMRA-MeOH, 6 JOE, 6,8-Difluoro-7-hydroxy-4-methylcoumarin pH 9.0, 6-Carboxyrhodamine 6G pH 7.0, 6-Carboxyrhodamine 6G, hydrochloride, 6-HEX, SE pH 9.0, 6-TET, SE pH 9.0, 7-Amino-4-methylcoumarin pH 7.0, 7-Hydroxy-4-methylcoumarin, 7-Hydroxy-4-methylcoumarin pH 9.0, Alexa 350, Alexa 405, Alexa 430, Alexa 488, Alexa 532, Alexa 546, Alexa 555, Alexa 568, Alexa 594, Alexa 647, Alexa 660, Alexa 680, Alexa 700, Alexa Fluor 430 antibody conjugate pH 7.2, Alexa Fluor 488 antibody conjugate pH 8.0, Alexa Fluor 488 hydrazide-water, Alexa Fluor 532 antibody conjugate pH 7.2, Alexa Fluor 555 antibody conjugate pH 7.2, Alexa Fluor 568 antibody conjugate pH 7.2, Alexa Fluor 610 R-phycoerythrin streptavidin pH 7.2, Alexa Fluor 647 antibody conjugate pH 7.2, Alexa Fluor 647 R-phycoerythrin streptavidin pH 7.2, Alexa Fluor 660 antibody conjugate pH 7.2, Alexa Fluor 680 antibody conjugate pH 7.2, Alexa Fluor 700 antibody conjugate pH 7.2, Allophycocyanin pH 7.5, AMCA conjugate, Amino Coumarin, APC (allophycocyanin), Atto 647, BCECF pH 5.5, BCECF pH 9.0, BFP (Blue Fluorescent Protein), BO-PRO-1-DNA, BO-PRO-3-DNA, BOBO-1-DNA, BOBO-3-DNA, BODIPY 650/665-X, MeOH, BODIPY FL conjugate, BODIPY FL, MeOH, Bodipy R6G SE, BODIPY R6G, MeOH, BODIPY TMR-X antibody conjugate pH 7.2, Bodipy TMR-X conjugate, BODIPY TMR-X, MeOH, BODIPY TMR-X, SE, BODIPY TR-X phalloidin pH 7.0, BODIPY TR-X, MeOH, BODIPY TR-X, SE, BOPRO-1, BOPRO-3, Calcein, Calcein pH 9.0, Calcium Crimson, Calcium Crimson Ca²⁺, Calcium Green, Calcium Green-1 Ca²⁺, Calcium Orange, Calcium Orange Ca²⁺, Carboxynaphthofluorescein pH 10.0, Cascade Blue, Cascade Blue BSA pH 7.0, Cascade Yellow, Cascade Yellow antibody conjugate pH 8.0, CFDA, CFP (Cyan Fluorescent Protein), CI-NERF pH 2.5, CI-NERF pH 6.0, Citrine, Coumarin, Cy 2, Cy 3, Cy 3.5, Cy 5, Cy 5.5, CyQUANT GR-DNA, Dansyl Cadaverine, Dansyl Cadaverine, MeOH, DAPI, DAPI-DNA, Dapoxyl (2-aminoethyl) sulfonamide, DDAO pH 9.0, Di-8 ANEPPS, Di-8-ANEPPS-lipid, Dil, DiO, DM-NERF pH 4.0, DM-NERF pH 7.0, DsRed, DTAF, dTomato, eCFP (Enhanced Cyan Fluorescent Protein), eGFP (Enhanced Green Fluorescent Protein), Eosin, Eosin antibody conjugate pH 8.0, Erythrosin-5-isothiocyanate pH 9.0, Ethidium Bromide, Ethidium homodimer, Ethidium homodimer-1-DNA, eYFP (Enhanced Yellow Fluorescent Protein), FDA, FITC, FITC antibody conjugate pH 8.0, FIAsH, Fluo-3, Fluo-3 Ca²⁺, Fluo-4, Fluor-Ruby, Fluorescein, Fluorescein 0.1 M NaOH, Fluorescein antibody conjugate pH 8.0, Fluorescein dextran pH 8.0, Fluorescein pH 9.0, Fluoro-Emerald, FM 1-43, FM 1-43 lipid, FM 4-64, FM 4-64, 2% CHAPS, Fura Red Ca²⁺, Fura Red, high Ca, Fura Red, low Ca, Fura-2 Ca²⁺, Fura-2, high Ca, Fura-2, no Ca, GFP (S65T), HcRed, Hoechst 33258, Hoechst 33258-DNA, Hoechst 33342, Indo-1 Ca²⁺, Indo-1, Ca free, Indo-1, Ca saturated, JC-1, JC-1 pH 8.2, Lissamine rhodamine, LOLO-1-DNA, Lucifer Yellow, CH, LysoSensor Blue, LysoSensor Blue pH 5.0, LysoSensor Green, LysoSensor Green pH 5.0, LysoSensor Yellow pH 3.0,

LysoSensor Yellow pH 9.0, LysoTracker Blue, LysoTracker Green, LysoTracker Red, Magnesium Green, Magnesium Green Mg²⁺, Magnesium Orange, Marina Blue, mBanana, mCherry, mHoneydew, MitoTracker Green, MitoTracker Green FM, MeOH, MitoTracker Orange, MitoTracker Orange, MeOH, MitoTracker Red, MitoTracker Red, MeOH, mOrange, mPlum, mRFP, mStrawberry, mTangerine, NBD-X, NBD-X, MeOH, NeuroTrace 500/525, green fluorescent Nissl stain-RNA, Nile Blue, EtOH, Nile Red, Nile Red-lipid, Nissl, Oregon Green 488, Oregon Green 488 antibody conjugate pH 8.0, Oregon Green 514, Oregon Green 514 antibody conjugate pH 8.0, Pacific Blue, Pacific Blue antibody conjugate pH 8.0, Phycoerythrin, PicoGreen dsDNA quantitation reagent, PO-PRO-1, PO-PRO-1-DNA, PO-PRO-3, PO-PRO-3-DNA, POPO-1, POPO-1-DNA, POPO-3, Propidium Iodide, Propidium Iodide-DNA, R-Phycoerythrin pH 7.5, ReAsH, Resorufin, Resorufin pH 9.0, Rhod-2, Rhod-2 Ca²⁺, Rhodamine, Rhodamine 110, Rhodamine 110 pH 7.0, Rhodamine 123, MeOH, Rhodamine Green, Rhodamine phalloidin pH 7.0, Rhodamine Red-X antibody conjugate pH 8.0, Rhodamine Green pH 7.0, Rhodol Green antibody conjugate pH 8.0, Sapphire, SBF1-Na⁺, Sodium Green Na⁺, Sulforhodamine 101, EtOH, SYBR Green I, SYPRO Ruby, SYTO 13-DNA, SYTO 45-DNA, SYTOX Blue-DNA, Tetramethylrhodamine antibody conjugate pH 8.0, Tetramethylrhodamine dextran pH 7.0, Texas Red-X antibody conjugate pH 7.2, TO-PRO-1-DNA, TO-PRO-3-DNA, TOTO-1-DNA, TOTO-3-DNA, TRITC, X-Rhod-1 Ca²⁺, YO-PRO-1-DNA, YO-PRO-3-DNA, YOYO-1-DNA, and YOYO-3-DNA.

[0064] In yet another embodiment, two types of fluorescent-labeled oligonucleotides attached to two different particles can be used as long as the nanoparticles have the ability to quench the detectable marker being utilized. Suitable particles include polymeric particles (such as, without limitation, polystyrene particles, polyvinyl particles, acrylate and methacrylate particles), glass particles, latex particles, Sepharose beads and others like particles well known in the art. Methods of attaching oligonucleotides to such particles are well known and routinely practiced in the art. See Chrisey et al., 1996, *Nucleic Acids Research*, 24: 3031-3039 (glass) and Charreyre et al., 1997 *Langmuir*, 13: 3103-3110, Fahy et al., 1993, *Nucleic Acids Research*, 21: 1819-1826, Elaissari et al., 1998, *J. Colloid Interface Sci.*, 202: 251-260, Kolarova et al., 1996, *Biotechniques*, 20: 196-198 and Wolf et al., 1987, *Nucleic Acids Research*, 15: 2911-2926 (polymer/latex).

[0065] Other labels besides fluorescent molecules are described, such as chemiluminescent molecules, which will give a detectable signal or a change in detectable signal upon hybridization.

NANOPARTICLES

[0066] As used herein, "nanoparticle" refers to small structures that are less than 10 μm , and preferably less than 5 μm , in any one dimension. In general, nanoparticles contemplated include any compound or substance with a high loading capacity for an oligonucleotide as described herein. Nanoparticles useful in the practice of the invention include metal (e.g., gold, silver, copper and platinum), semiconductor (e.g., CdSe, CdS, and CdS or CdSe coated with ZnS) and magnetic (e.g., ferromagnetite) colloidal materials, as long as the nanoparticle has the ability to quench the otherwise detectable marker. Other nanoparticles useful in the practice of the invention include ZnS, ZnO, TiO₂, AgI, AgBr, HgI₂, PbS, PbSe, ZnTe, CdTe, In₂S₃, In₂Se₃, Cd₃P₂, Cd₃As₂, InAs, and GaAs. The size of the nanoparticles is preferably from about 5 nm to about 150 nm (mean diameter), more preferably from about 5 to about 50 nm, most preferably from about 10 to about 30 nm. The size of the nanoparticle is contemplated to be from about 5 to about 10 nm, or about 5 to about 20 nm, or about 5 to about 30 nm, or about 5 to about 40 nm, or about 5 to about 60 nm, or about 5 to about 70 nm, or about 5 to about 80 nm, or about 5 to about 90 nm, or about 5 to about 100 nm, or about 5 to about 110 nm, or about 5 to about 120 nm, or about 5 to about 130 nm, or about 5 to about 140 nm, or about 10 to about 20 nm, or about 10 to about 40 nm, or about 10 to about 50 nm, or about 10 to about 60 nm, or about 10 to about 70 nm, or about 10 to about 80 nm, or about 10 to about 90 nm, or about 10 to about 100 nm, or about 10 to about 110 nm, or about 10 to about 120 nm, or about 10 to about 130 nm, or about 10 to about 140 nm, or about 10 to about 150 nm. The nanoparticles may also be rods, prisms, or tetrahedra.

[0067] Thus, nanoparticles are contemplated for use in the methods which comprise a variety of inorganic materials including, but not limited to, metals, semi-conductor materials or ceramics as described in US patent application No 20030147966. For example, metal-based nanoparticles include those described herein. Ceramic nanoparticle materials include, but are not limited to, brushite, tricalcium phosphate, alumina, silica, and zirconia. Organic materials from which nanoparticles are produced include carbon. Nanoparticle polymers include polystyrene, silicone rubber, polycarbonate, polyurethanes, polypropylenes, polymethylmethacrylate, polyvinyl chloride, polyesters, polyethers, and polyethylene. Biodegradable, biopolymer (e.g. polypeptides such as BSA, polysaccharides, etc.), other biological materials (e.g. carbohydrates), and/or polymeric compounds are also contemplated for use in producing nanoparticles.

[0068] In practice, methods are provided using any suitable nanoparticle having molecules attached thereto that are in general suitable for use in detection assays known in the art to the extent and do not interfere with polynucleotide complex formation, i.e., hybridization to form a double-strand or triple-strand complex. The size, shape and chemical composition of the particles contribute to the properties of the resulting oligonucleotide-functionalized nanoparticle. These properties include for example, optical properties, optoelectronic properties, electrochemical properties, electronic properties, stability in various solutions, magnetic properties, and pore and channel size variation. The use of mixtures

of particles having different sizes, shapes and/or chemical compositions, as well as the use of nanoparticles having uniform sizes, shapes and chemical composition, is contemplated. Examples of suitable particles include, without limitation, nanoparticles, aggregate particles, isotropic (such as spherical particles) and anisotropic particles (such as non-spherical rods, tetrahedral, prisms) and core-shell particles such as the ones described in U.S. patent application Ser. No. 10/034,451, filed Dec. 28, 2002 and International application no. PCT/US01/50825, filed Dec. 28, 2002.

[0069] Methods of making metal, semiconductor and magnetic nanoparticles are well-known in the art. See, for example, Schmid, G. (ed.) Clusters and Colloids (VCH, Weinheim, 1994); Hayat, M. A. (ed.) Colloidal Gold: Principles, Methods, and Applications (Academic Press, San Diego, 1991); Massart, R., IEEE Transactions On Magnetism, 17, 1247 (1981); Ahmadi, T. S. et al., Science, 272, 1924 (1996); Henglein, A. et al., J. Phys. Chem., 99, 14129 (1995); Curtis, A. C. et al., Angew. Chem. Int. Ed. Engl., 27, 1530 (1988). Preparation of polyalkylcyanoacrylate nanoparticles prepared is described in Fattal, et al., J. Controlled Release (1998) 53: 137-143 and US Patent No. 4,489,055. Methods for making nanoparticles comprising poly(D-glucaramidoamine)s are described in Liu, et al., J. Am. Chem. Soc. (2004) 126:7422-7423. Preparation of nanoparticles comprising polymerized methylmethacrylate (MMA) is described in Tondelli, et al., Nucl. Acids Res. (1998) 26:5425-5431, and preparation of dendrimer nanoparticles is described in, for example Kukowska-Latallo, et al., Proc. Natl. Acad. Sci. USA (1996) 93:4897-4902 (Starburst polyamidoamine dendrimers).

[0070] Suitable nanoparticles are also commercially available from, for example, Ted Pella, Inc. (gold), Amersham Corporation (gold) and Nanoprobes, Inc. (gold).

[0071] Also as described in US patent application No 20030147966, nanoparticles comprising materials described herein are available commercially or they can be produced from progressive nucleation in solution (e.g., by colloid reaction), or by various physical and chemical vapor deposition processes, such as sputter deposition. See, e.g., HaVashi, (1987) Vac. Sci. Technol. July/August 1987, A5(4):1375-84; Hayashi, (1987) Physics Today, December 1987, pp. 44-60; MRS Bulletin, January 1990, pgs. 16-47.

[0072] As further described in US patent application No 20030147966, nanoparticles contemplated are produced using HAuCl_4 and a citrate-reducing agent, using methods known in the art. See, e.g., Marinakos et al., (1999) Adv. Mater. 11: 34-37; Marinakos et al., (1998) Chem. Mater. 10: 1214-19; Enustun & Turkevich, (1963) J. Am. Chem. Soc. 85: 3317. Tin oxide nanoparticles having a dispersed aggregate particle size of about 140 nm are available commercially from Vacuum Metallurgical Co., Ltd. of Chiba, Japan. Other commercially available nanoparticles of various compositions and size ranges are available, for example, from Vector Laboratories, Inc. of Burlingame, Calif.

NANOPARTICLE FUNCTIONALIZED WITH STRUCTURE-SWITCHING RECOGNITION SEQUENCE

[0073] In other embodiments, the detectable change is created by labeling the oligonucleotides with fluorescent molecules and dyes that produce detectable changes upon hybridization of the oligonucleotides on the nanoparticles. In one aspect, for example, oligonucleotides functionalized on nanoparticles have a marker attached to the terminus distal to the nanoparticle attachment terminus, and in the absence of association with a target, the distal terminus with the marker is positioned in proximity to the nanoparticle close enough to quench fluorescence of the marker. In one aspect, metal and semiconductor nanoparticles are known fluorescence quenchers, with the magnitude of the quenching effect depending on the distance between the nanoparticles and the fluorescent molecule. Thus, in the single-strand state, the oligonucleotides attached to the nanoparticles interact with the nanoparticles through, e.g., a hairpin structure formed by the oligonucleotide through secondary structure folding, which brings the fluorescent molecule in proximity to the nanoparticle, so that significant quenching is observed. Similarly, in the unbound state, polypeptides attached to the nanoparticles would assume a conformation that would bring the marker into proximity with the nanoparticle and the marker would be quenched. Upon polynucleotide or polypeptide complex formation due to target molecule binding via the recognition sequence, the fluorescent molecule will become spaced away from the nanoparticles, diminishing quenching of the fluorescence (Figure 1). Useful lengths of the oligonucleotides can be determined empirically. Thus, in various aspects, metallic and semiconductor nanoparticles having fluorescent-labeled oligonucleotides or polypeptides attached thereto are used in any of the assay formats described herein.

ATTACHING OLIGONUCLEOTIDES TO NANOPARTICLES

[0074] Nanoparticles for use in the methods provided are functionalized with an oligonucleotide, or modified form thereof, which is from about 5 to about 100 nucleotides in length. Methods are also contemplated wherein the oligonucleotide is about 5 to about 90 nucleotides in length, about 5 to about 80 nucleotides in length, about 5 to about 70 nucleotides in length, about 5 to about 60 nucleotides in length, about 5 to about 50 nucleotides in length about 5 to about 45 nucleotides in length, about 5 to about 40 nucleotides in length, about 5 to about 35 nucleotides in length, about 5 to about 30 nucleotides in length, about 5 to about 25 nucleotides in length, about 5 to about 20 nucleotides in length, about 5 to about 15 nucleotides in length, about 5 to about 10 nucleotides in length, and all oligonucleotides intermediate in length of the sizes specifically disclosed to the extent that the oligonucleotide is able to achieve the

desired result. Accordingly, oligonucleotides of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 1, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, and 100 nucleotides in length are contemplated.

5 **[0075]** In still other aspects, oligonucleotides comprise from about 8 to about 80 nucleotides (i.e. from about 8 to about 80 linked nucleosides). One of ordinary skill in the art will appreciate that methods utilize compounds of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleotide in length.

10 **[0076]** The nanoparticles, the oligonucleotides or both are functionalized in order to attach the oligonucleotides to the nanoparticles. Such methods are known in the art. For instance, oligonucleotides functionalized with alkanethiols at their 3'-termini or 5'-termini readily attach to gold nanoparticles. See Whitesides, 1995, Proceedings of the Robert A. Welch Foundation 39th Conference On Chemical Research Nanophase Chemistry, Houston, Tex., pages 109-121. See also, Mucic et al., 1996, Chem. Commun. 555-557 (describes a method of attaching 3' thiol DNA to flat gold surfaces; this method can be used to attach oligonucleotides to nanoparticles). The alkanethiol method can also be used to attach oligonucleotides to other metal, semiconductor and magnetic colloids and to the other nanoparticles listed above. Other functional groups for attaching oligonucleotides to solid surfaces include phosphorothioate groups (see, e.g., U.S. Pat. No. 5,472,881 for the binding of oligonucleotide-phosphorothioates to gold surfaces), substituted alkylsiloxanes (see, e.g. Burwell, 1974, Chemical Technology, 4: 370-377 and Matteucci and Caruthers, 1981, J. Am. Chem. Soc., 103: 3185-3191 for binding of oligonucleotides to silica and glass surfaces, and Grabar et al., 1995, Anal. Chem., 67: 735-743 for binding of aminoalkylsiloxanes and for similar binding of mercaptoalkylsiloxanes). Oligonucleotides terminated with a 5' thionucleoside or a 3' thionucleoside may also be used for attaching oligonucleotides to solid surfaces. The following references describe other methods which may be employed to attach oligonucleotides to nanoparticles: Nuzzo et al., 1987, J. Am. Chem. Soc., 109: 2358 (disulfides on gold); Allara and Nuzzo, 1985, Langmuir, 1: 45 (carboxylic acids on aluminum); Allara and Tompkins, 1974, J. Colloid Interface Sci., 49: 410-421 (carboxylic acids on copper); Iler, The Chemistry Of Silica, Chapter 6, (Wiley 1979) (carboxylic acids on silica); Timmons and Zisman, 1965, J. Phys. Chem., 69: 984-990 (carboxylic acids on platinum); Soriaga and Hubbard, 1982, J. Am. Chem. Soc., 104: 3937 (aromatic ring compounds on platinum); Hubbard, 1980, Acc. Chem. Res., 13: 177 (sulfolanes, sulfoxides and other functionalized solvents on platinum); Hickman et al., 1989, J. Am. Chem. Soc., 111: 7271 (isonitriles on platinum); Maoz and Sagiv, 1987, Langmuir, 3: 1045 (silanes on silica); Maoz and Sagiv, 1987, Langmuir, 3: 1034 (silanes on silica); Wasserman et al., 1989, Langmuir, 5: 1074 (silanes on silica); Eltekova and Eltekov, 1987, Langmuir, 3: 951 (aromatic carboxylic acids, aldehydes, alcohols and methoxy groups on titanium dioxide and silica); Lec et al., 1988, J. Phys. Chem., 92: 2597 (rigid phosphates on metals). Additionally, any suitable method for attaching oligonucleotides onto the nanoparticle surface may be used. A particularly preferred method for attaching oligonucleotides onto a surface is based on an aging process described in U.S. application Ser. No. 09/344,667, filed Jun. 25, 1999; Ser. No. 09/603,830, filed Jun. 26, 2000; Ser. No. 09/760,500, filed Jan. 12, 2001; Ser. No. 09/820,279, filed Mar. 28, 2001; Ser. No. 09/927,777, filed Aug. 10, 2001; and in International application nos. PCT/US97/12783, filed Jul. 21, 1997; PCT/US00/17507, filed Jun. 26, 2000; PCT/US01/01190, filed Jan. 12, 2001; PCT/US01/10071, filed Mar. 28, 2001.

25 The aging process provides nanoparticle-oligonucleotide conjugates with unexpected enhanced stability and selectivity. The method comprises providing oligonucleotides preferably having covalently bound thereto a moiety comprising a functional group which can bind to the nanoparticles. The moieties and functional groups are those that allow for binding (i.e., by chemisorption or covalent bonding) of the oligonucleotides to nanoparticles. For instance, oligonucleotides having an alkanethiol, an alkanedisulfide or a cyclic disulfide covalently bound to their 5' or 3' ends can be used to bind the oligonucleotides to a variety of nanoparticles, including gold nanoparticles.

30 **[0077]** The oligonucleotides are contacted with the nanoparticles in water for a time sufficient to allow at least some of the oligonucleotides to bind to the nanoparticles by means of the functional groups. Such times can be determined empirically. For instance, it has been found that a time of about 12-24 hours gives good results. Other suitable conditions for binding of the oligonucleotides can also be determined empirically. For instance, a concentration of about 10-20 nM nanoparticles and incubation at room temperature gives good results.

35 **[0078]** Next, at least one salt is added to the water to form a salt solution. The salt can be any suitable water-soluble salt. For instance, the salt may be sodium chloride, magnesium chloride, potassium chloride, ammonium chloride, sodium acetate, ammonium acetate, a combination of two or more of these salts, or one of these salts in phosphate buffer. Preferably, the salt is added as a concentrated solution, but it could be added as a solid. The salt can be added to the water all at one time or the salt is added gradually over time. By "gradually over time" is meant that the salt is added in at least two portions at intervals spaced apart by a period of time. Suitable time intervals can be determined empirically.

40 **[0079]** The ionic strength of the salt solution must be sufficient to overcome at least partially the electrostatic repulsion of the oligonucleotides from each other and, either the electrostatic attraction of the negatively-charged oligonucleotides for positively-charged nanoparticles, or the electrostatic repulsion of the negatively-charged oligonucleotides from neg-

atively-charged nanoparticles. Gradually reducing the electrostatic attraction and repulsion by adding the salt gradually over time has been found to give the highest surface density of oligonucleotides on the nanoparticles. Suitable ionic strengths can be determined empirically for each salt or combination of salts. A final concentration of sodium chloride of from about 0.1 M to about 1.0 M in phosphate buffer, preferably with the concentration of sodium chloride being increased gradually over time, has been found to give good results.

[0080] After adding the salt, the oligonucleotides and nanoparticles are incubated in the salt solution for an additional period of time sufficient to allow sufficient additional oligonucleotides to bind to the nanoparticles to produce the stable nanoparticle-oligonucleotide conjugates. As will be described in detail below, an increased surface density of the oligonucleotides on the nanoparticles has been found to stabilize the conjugates. The time of this incubation can be determined empirically. A total incubation time of about 24-48, preferably 40 hours, has been found to give good results (this is the total time of incubation; as noted above, the salt concentration can be increased gradually over this total time). This second period of incubation in the salt solution is referred to herein as the "aging" step. Other suitable conditions for this "aging" step can also be determined empirically. For instance, incubation at room temperature and pH 7.0 gives good results.

[0081] The conjugates produced by use of the "aging" step have been found to be considerably more stable than those produced without the "aging" step. As noted above, this increased stability is due to the increased density of the oligonucleotides on the surfaces of the nanoparticles which is achieved by the "aging" step. An alternative "fast salt aging" process produced particles with comparable DNA densities and stability. By performing the salt additions in the presence of a surfactant, for example approximately 0.01% sodium dodecylsulfate (SDS), Tween, or polyethylene glycol (PEG), the salt aging process can be performed in about an hour.

[0082] The surface density achieved by the "aging" step will depend on the size and type of nanoparticles and on the length, sequence and concentration of the oligonucleotides. A surface density adequate to make the nanoparticles stable and the conditions necessary to obtain it for a desired combination of nanoparticles and oligonucleotides can be determined empirically. Generally, a surface density of at least 10 picomoles/cm² will be adequate to provide stable nanoparticle-oligonucleotide conjugates. Preferably, the surface density is at least 15 picomoles/cm². Since the ability of the oligonucleotides of the conjugates to hybridize with nucleic acid and oligonucleotide targets can be diminished if the surface density is too great, the surface density is preferably no greater than about 35-40 picomoles/cm². Methods are also provided wherein the oligonucleotide is bound to the nanoparticle at a surface density of at least 10 pmol/cm², at least 15 pmol/cm², at least 20 pmol/cm², at least 25 pmol/cm², at least 30 pmol/cm², at least 35 pmol/cm², at least 40 pmol/cm², at least 45 pmol/cm², at least 50 pmol/cm², or 50 pmol/cm² or more.

[0083] "Hybridization," which is used interchangeably with the term "complex formation" herein, means an interaction between two or three strands of nucleic acids by hydrogen bonds in accordance with the rules of Watson-Crick DNA complementarity, Hoogstein binding, or other sequence-specific binding known in the art. Alternatively it can mean an interaction between polypeptides as defined herein in accordance with sequence-specific binding properties known in the art. Hybridization can be performed under different stringency conditions known in the art. Under appropriate stringency conditions, hybridization between the two complementary strands or two polypeptides could reach about 60% or above, about 70% or above, about 80% or above, about 90% or above, about 95% or above, about 96% or above, about 97% or above, about 98% or above, or about 99% or above in the reactions.

[0084] In various aspects, the methods include use of two or three oligonucleotides or polypeptides which are 100% complementary to each other, *i.e.*, a perfect match, while in other aspects, the individual oligonucleotides are at least (meaning greater than or equal to) about 95% complementary to each over the all or part of length of each oligonucleotide, at least about 90%, at least about 85%, at least about 80%, at least about 75%, at least about 70%, at least about 65%, at least about 60%, at least about 55%, at least about 50%, at least about 45%, at least about 40%, at least about 35%, at least about 30%, at least about 25%, at least about 20% complementary to each other.

[0085] It is understood in the art that the sequence of the oligonucleotide used in the methods need not be 100% complementary to each other to be specifically hybridizable. Moreover, oligonucleotide may hybridize to each other over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (*e.g.*, a loop structure or hairpin structure). Percent complementarity between any given oligonucleotide can be determined routinely using BLAST programs (Basic Local Alignment Search Tools) and PowerBLAST programs known in the art (Altschul et al., 1990, J. Mol. Biol., 215: 403-410; Zhang and Madden, 1997, Genome Res., 7: 649-656).

[0086] In one aspect, methods are provided wherein the packing density of the oligonucleotides on the surface of the nanoparticle is sufficient to result in cooperative behavior between nanoparticles and between polynucleotide strands on a single nanoparticle. In another aspect, the cooperative behavior between the nanoparticles increases the resistance of the oligonucleotide to degradation.

[0087] As used herein, "stable" means that, for a period of at least six months after the conjugates are made, a majority of the oligonucleotides remain attached to the nanoparticles and the oligonucleotides are able to hybridize with nucleic acid and oligonucleotide targets under standard conditions encountered in methods of detecting nucleic acid and methods of nanofabrication.

[0088] Each nanoparticle utilized in the methods provided has a plurality of oligonucleotides attached to it. As a result, each nanoparticle-oligonucleotide conjugate has the ability to hybridize to a second oligonucleotide that is conjugated to a fluorophore detectably distinct from the fluorophore present on the first nanoparticle-oligonucleotide conjugate and functionalized on a second nanoparticle, and when present, a free oligonucleotide, having a sequence sufficiently complementary. In one aspect, methods are provided wherein each nanoparticle is functionalized with identical oligonucleotides, *i.e.*, each oligonucleotide attached to the nanoparticle has the same length and the same sequence. In other aspects, each nanoparticle is functionalized with two or more oligonucleotides which are not identical, *i.e.*, at least one of the attached oligonucleotides differ from at least one other attached oligonucleotide in that it has a different length and/or a different sequence.

[0089] The term "oligonucleotide" or "polynucleotide" includes those wherein a single sequence is attached to a nanoparticle, or multiple copies of the single sequence are attached. For example, in various aspects, an oligonucleotide is present in multiple copies in tandem, for example, two, three, four, five, six, seven eight, nine, ten or more tandem repeats.

[0090] Alternatively, the nanoparticle is functionalized to include at least two oligonucleotides having different sequences with the proviso that each oligonucleotide is labeled with a detectably distinct marker. As above, the different oligonucleotide sequences are in various aspects arranged in tandem and/or in multiple copies. Alternatively, the oligonucleotides having different sequences are attached directly to the nanoparticle. In methods wherein oligonucleotides having different sequences are attached to the nanoparticle, aspects of the methods include those wherein the different oligonucleotide sequences hybridize to different regions on the same polynucleotide.

[0091] The oligonucleotides on the nanoparticles may all have the same sequence or may have different sequences that hybridize with different portions of the polynucleotide attached to another nanoparticle. When oligonucleotides having different sequences are used, each nanoparticle may have all of the different oligonucleotides attached to it or the different oligonucleotides are attached to different nanoparticles. Alternatively, the oligonucleotides on each of the nanoparticles may have a plurality of different sequences, at least one of which must hybridize with a portion of the polynucleotide on a second nanoparticle.

NANO-FLARE TECHNOLOGY

[0092] In an aspect of the present invention, an oligonucleotide or polypeptide containing the recognition sequence in the binding moiety that is attached to the nanoparticle as described herein. "Recognition sequence" as used herein is understood to mean a sequence that is partially or completely complementary to a target molecule of interest.

[0093] The nanoparticle with attached oligonucleotide binding moiety that contains a recognition sequence is initially associated with a reporter sequence. As used herein, a "reporter sequence" is understood to mean a sequence that is partially or completely complementary and therefore able to hybridize to the binding moiety and its recognition sequence. The reporter sequence is labeled as discussed herein above, and is also referred to as a nano-flare. Further, the reporter sequence is in various aspects comprised of fewer, the same or more bases than the recognition sequence, such that binding of the recognition sequence in the binding moiety to its target molecule causes release of the hybridized reporter sequence, thereby resulting in a detectable and measurable change in the label attached to the reporter sequence (Figure 2).

[0094] In one specific aspect, nanoparticles functionalized with a recognition sequence for a specific target mRNA are hybridized with a short complementary Cy5 labeled reporter polynucleotide having a reporter sequence and where the fluorescence of the Cy5 portion is quenched when hybridized to the recognition sequence on the nanoparticle. This reporter sequence is also capable of being displaced by the target mRNA. Upon displacement, the Cy5 portion is no longer quenched and fluoresces, allowing for detection and quantification of a fluorescent signal, which is correlated to the amount of target sequence hybridized to the recognition sequence with concomitant displacement of the reporter sequence.

[0095] Nano-flares take advantage of the unique optical properties of gold nanoparticles (Au NPs). Au NPs quench fluorescence with a greater efficiency (Dubertret et al., 2001, Nat. Biotechnol. 19: 365-370) and over greater distances (Dulkeith et al., 2005, Nano Lett. 5: 585-589) than molecular quenchers. Likewise, all other types of nanoparticles described herein may be used as long as they are able to quench the detectable marker of an attached binding moiety.

[0096] Those of skill in the art are able to determine relative melting temperatures and/or hybridization conditions in the case of *in vitro* studies without undue experimentation that will facilitate reporter binding to the recognition sequence in the absence of the target molecule while resulting in displacement of said reporter sequence in the presence of said target molecule.

[0097] The invention is illustrated by the following examples, which are not intended to be limiting in any way.

EXAMPLES

Example 1

5 [0098] This example is meant to demonstrate that fluorescently labeled oligonucleotide-modified gold nanoparticle agents can be used to detect intracellular molecule targets. As a proof-of-concept, it is demonstrated that intracellular detection of mRNA targets in two cell-types using fluorescently labeled oligonucleotide-modified gold nanoparticles is highly effective. These agents readily enter the cells and produce a fluorescent signal that can easily be read using both fluorescent microscopy and flow-cytometry.

10 [0099] Specifically, 13 nm gold nanoparticles were modified with several different sequences that are terminated on one end with a thiol moiety, on the other end with a fluorescent dye, and contain a structure-switching recognition sequence. In the absence of the target, the dye molecule is in close proximity with the gold nanoparticle surface, which leads to quenching and no fluorescent signal. In the presence of the target, the dye molecule is separated from the gold nanoparticle surface and a fluorescent signal is observed (Figure 1.).

15 [0100] Au NPs were functionalized with thiolated oligonucleotides containing an 18-base recognition element to a specific RNA transcript (Figure 1) via gold thiol bond formation (Love et al., 2005, Chem. Rev. 105: 1103-1169). Oligonucleotide functionalized Au NPs were then allowed to hybridize with short cyanine (Cy5) dye-terminated reporter sequences capable of acting as "flares" when displaced by a longer target or target region (Figure 1). In the bound state, the Cy5 fluorescence of the reporter strand is quenched due to proximity to the Au NP surface. In the presence of a target, the flare strand is displaced and liberated from the Au NP by forming the longer and more stable duplex between the target and the oligonucleotide-modified Au NP.

Example 2

25 [0101] To further exemplify the use of the gold nanoparticles' ability to enter cells and detect intracellular target molecules, *in vitro* cell culture experiments were carried out.

30 [0102] C166 mammalian cells that stably express the enhanced green fluorescence protein were maintained in Dulbecco's Modified Eagles Medium with 10% serum at 37° C and 5% CO₂ and dosed with fluorescently labeled oligonucleotide-modified gold nanoparticle agents that target the enhanced green fluorescence (EGFP) protein mRNA. SKBR3 human breast cancer (*vide infra*) and C166 mouse endothelial cells were obtained from the American Tissue Culture Collection (ATCC) and were grown in McCoy's 5A Medium and Dulbecco's Modified Eagles medium (DMEM), respectively, with 10% heat inactivated fetal bovine serum and maintained at 37° C in 5% CO₂. Cells were seeded in 6 or 24 well plates and grown for 1-2 days prior to treatment. On the day of treatment, the cells were approximately 50% confluent. The media was replaced with fresh media containing the functionalized Au NPs.

35 [0103] Control experiments were performed with particles containing targeting regions for the anthrax RNA, which is not present in mammalian cells. After transfection for 16 hour, these EGFP-expressing cells treated with the EGFP targeting probes displayed a bright fluorescent signal, much greater than the signal observed in the control particles. As a further control experiment, the particles were tested in C166 cells that do not express EGFP and hence do not contain the EGFP mRNA target. In these experiments neither probe was found to signal once inside the cells, thus confirming that fluorescently labeled oligonucleotide-modified gold nanoparticle agents can be used to detect specific intercellular molecules targets.

40 [0104] The probe entry into the cells was confirmed using inductivity-coupled plasma mass spectrometry in order to quantify the uptake and also rule out any sequence dependent uptake effects. These data confirm that after a typical experiment, the cells contain approximately 100,000 gold nanoparticles, and that the C 166 cells take-up a similar number of gold nanoparticles regardless of the recognition sequence contained in the oligonucleotides.

Example 3

50 [0105] The fluorescently labeled oligonucleotide-modified gold nanoparticle agents were further examined for their oligonucleotide loading and fluorescence signaling ability. The results of these experiments confirm that each gold nanoparticle is functionalized with approximately 60 fluorescent oligonucleotides that contain the recognition sequence. Furthermore, when a 1 nM solution of the various oligonucleotide-modified gold nanoparticle agents were digested in a KCN solution, they all displayed a nearly identical florescence. Taken together this characterization data indicates that in the absence of target, the fluorescently labeled oligonucleotide-modified gold nanoparticle agents display an identical fluorescence signal, further confirming that the intracellular signaling observed was caused by a specific intracellular binding event.

55 [0106] The detection of endogenous genes is of particular importance for drug discovery and genetic research. Thus, gold nanoparticles were prepared that can be used to sense the presence of the cancer gene survivin. These particles,

when compared control sequences, again display a bright fluorescent signal from inside survivin expressing A549 lung cancer cells. These results indicate that the described fluorescently labeled oligonucleotide-modified gold nanoparticle agents can be used to directly read out the presence of a native mRNA target.

[0107] The fluorescence signals that were observed can alternatively be detected in large populations of the treated cells using a simple, bench-top flow cytometer instrument. These experiments again highlight the very efficient uptake efficiency that is observed for these fluorescently labeled oligonucleotide-modified gold nanoparticle agents, and also that nearly all cells in a given sample show strong signal indicating the presence of an intracellular mRNA target. Here, 1000 cell counts were plotted as a function of their fluorescence intensity using a Guava Easy Cyte flow cytometer and the instruments software. In these experiments it was observed that a dramatic shift in the fluorescence of the population of the survivin expressing A549 cells was seen when they were treated with the survivin targeting fluorescently labeled oligonucleotide-modified gold nanoparticle agents, relative to those treated with the control anthrax targeting agents. The results indicate that when coupled to flow-cytometry, fluorescently labeled oligonucleotide-modified gold nanoparticle agents are well-suited for sorting large populations of cells.

[0108] Also compared was the efficiency of the particle with a conventional quencher-fluorophore oligonucleotide sequence that has been transfected into the cells with the Lipofectamine 2000 formulation. Under the analogous conditions where our particles showed dramatic signaling ability, these formulations show a negligible signaling ability. Even when their concentration was increased 10 times, they showed little or no signal, thus proving that under these conditions, the nanoparticles outperform a conventional quencher-fluorophore oligonucleotide probe.

[0109] Taken in sum, the foregoing examples show that:

1) The gold nanoparticles assist in the intracellular delivery of a fluorophore containing oligonucleotide that is capable of detecting a target.

2) These fluorescently labeled oligonucleotide-modified gold nanoparticle agents can be used to detect both endogenous and exogenous intracellular targets.

3) The fluorescent signal that indicates the presence of the specific mRNA target can be read by either a fluorescent microscope or a flow-cytometer.

4) The efficient uptake of these agents and their high signaling ability makes them well suited for sorting large cell populations.

5) The efficient uptake of these agents and their high signaling ability surpasses conventional quencher-fluorophore oligonucleotide probe under the conditions studied.

6) The principles can be extended to other structure-switching recognition sequences such as nucleic acid aptamers and peptides.

[0110] Additional fluorescently labeled aptamer-containing particle probes that target the molecule adenosine triphosphate (ATP) are also contemplated by the present invention.

[0111] The present invention also contemplates the ability to simultaneously detect multiple intracellular targets, and quantify their intracellular concentrations in real time. The principles can be applied to real-time monitoring cell function in higher organisms.

Example 4

[0112] Nano-flares have been prepared using 13 nm Au NPs, since this size particle is an efficient quencher, can be densely functionalized with oligonucleotides (Mirkin et al., 1996, Nature 382: 607-609), and does not efficiently scatter visible light, which is important for designing optical probes with minimal interference.

[0113] Au NPs were functionalized with thiolated oligonucleotides containing a recognition element to a specific RNA transcript (Figure 2) via gold thiol bond formation (Love et al., 2005, Chem. Rev. 105: 1103-1169). Oligonucleotides were synthesized on an Expedite 8909 Nucleotide Synthesis System (ABI) using standard solid-phase phosphoramidite methodology. Bases and reagents were purchased from Glen Research. Oligonucleotides were purified by reverse-phase high performance liquid chromatography (HPLC). To prepare nano flare probes, citrate-stabilized gold nanoparticles (13 ± 1 nm) were prepared using published procedures (Frens, G., 1973, Nature-Physical Science 241: 20-22). Thiol-modified oligonucleotides were added to 13 ± 1 nm gold colloids at a concentration of 3 nmol of oligonucleotide per 1 mL of 10 nM colloid and shaken overnight. After 12 hours, sodium dodecylsulfate (SDS) solution (10%) was added to the mixture to achieve a 0.1 % SDS concentration. Phosphate buffer (0.1 M; pH 7.4) was added to the mixture to

EP 2 121 987 B1

achieve a 0.01 M phosphate concentration, and six aliquots of sodium chloride solution (2.0 M) were then added to the mixture over an eight-hour period to achieve a final sodium chloride concentration of 0.15 M. The mixture was shaken overnight to complete the functionalization process. The solution containing the functionalized particles was centrifuged (13,000 rpm, 20 min) and resuspended in phosphate buffered saline (PBS; 137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl, pH 7.4, Hyclone) three times to produce the purified Au NPs used in all subsequent experiments. The concentration of the particles was determined by measuring their extinction at 524 nm ($\epsilon = 2.7 \times 10^8 \text{ L mol}^{-1} \text{ cm}^{-1}$). Purified, oligonucleotide functionalized Au NPs were suspended to a concentration of 10 nM in PBS (PBS; 137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl, pH 7.4, Hyclone) containing 100 nM of the complementary Cy5 labeled reporter sequence. The mixture was heated to 70° C, slowly cooled to room temperature, and stored in the dark for at least 12 hours to allow hybridization. Particles were filter sterilized using a 0.2 μm acetate syringe filter (GE Healthcare). The oligonucleotide sequences that were used are as follows:

Recognition Sequence: 5' -CTT GAG AAA GGG CTG CCA AAA AA-SH-3'
(SEQ ID NO. 1)

Reporter Sequence: 3' -CCC GAC GGT T-Cy5-5' (SEQ ID NO. 2)

Target Region: 3'-GAA CTC TTT CCC GAC GGT-5' (SEQ ID NO. 3)

[0114] Nano-flare probes or molecular beacons were diluted to a concentration of 1 nM in PBS containing 0.1 % Tween 20 (Sigma) and treated with a complementary target (target concentration, 1 μM). The fluorescence spectra were recorded on a Jobin Yvon Fluorolog FL3-22 exciting at 633 nm and measuring emission from 650 to 750 nm in 1 nm increments. Oligonucleotide functionalized Au NPs were then allowed to hybridize with short cyanine (Cy5) dye-terminated reporter sequences capable of acting as "flares" when displaced by a longer target or target region. In the bound state, the Cy5 fluorescence of the reporter strand is quenched due to proximity to the Au NP surface. In the presence of a target, the flare strand is displaced and liberated from the Au NP by forming the longer and more stable duplex between the target and the oligonucleotide-modified Au NP.

[0115] Testing the nano-flare design using synthetic complementary targets demonstrates that the probes respond with a 3.8-fold increase in fluorescence signal upon target recognition and binding. In contrast, the signal does not change in the presence of a non-complementary target, and is of comparable magnitude to background fluorescence. These results thus demonstrate that nano-flares are efficient at signaling the presence of a specific target.

Example 5

[0116] Having established the signaling ability of nano-flare probes with synthetic targets, their ability to enter, visualize and detect RNA targets in live cells was investigated. Nano-flares were designed to incorporate a complementary region for the survivin transcript, a target that has received significant attention due to its potential use in cancer therapeutics and diagnostics (Altieri et al., 2003, Oncogene 22: 8581-8589). The SKBR3 cell line (human breast cancer), which expresses a high number of survivin transcripts (Peng et al., 2005, Cancer Res. 65: 1909-1917), was used as a model to test survivin-targeting nano-flares. The survivin recognition and reporter sequences are as shown above (SEQ ID NO. 1 and SEQ ID NO. 2). As a control, a second probe containing a non-complementary sequence was prepared. The non-complementary probe was designed and determined to have similar background fluorescence, melting properties, and signaling ability as the survivin probe. The survivin control probe oligonucleotide sequence was:

Control particle recognition sequence: 5' -CTA TCG CGT ACA ATC TGC AAA AA-SH-3' (SEQ ID NO. 4)

Control particle reporter sequence: 3' -GCA TGT TAG ACG T-Cy5-5' (SEQ ID NO. 5)

Survivin molecular beacon: 5' -Cy5-CGA CGG AGA AAG GGC TGC CAC GTC G dabcy1-3' (SEQ ID NO. 6)

Control molecular beacon, 5' -Cy5-CGA CGT CGC GTA CAA TCT GCC GTC G-dabcy1-3' (SEQ ID NO. 7)

5 **[0117]** Cells were cultured on glass microscope cover slips, incubated with nano-flares, and imaged using scanning confocal microscopy. Specifically, cells were grown on glass coverslips placed at the bottom of 6 well tissue culture plates. After 1 day, the media was replaced with media containing nano-flares (particle concentration, 125 pM). After 6 hours of treatment, the media was replaced, and the cells were cultured for an additional 12 hours. The coverslips were removed, washed with PBS, and fixed to a chamber filled with PBS mounted on a glass slide. All images were obtained with a Zeiss 510 LSM at 63x magnification using a 633 nm HeNe laser excitation source.

10 **[0118]** SKBR3 cells treated with survivin nano-flares were highly fluorescent as compared to those treated with the non-complementary controls. To further confirm that this signaling is consistent with the presence of survivin, a C166 cell-line (mouse endothelial) was used as a control since it does not contain the human survivin transcript. C166 cells were treated with both the survivin and control probes. In this case, no distinguishable difference in the fluorescence of the cells was observed after treatment. These imaging results were consistent with reverse transcriptase PCR (RT-PCR) measurements (*vide infra*).

15 **[0119]** In order to quantify the intracellular signaling of the nano-flares, cells treated with probes were examined using analytical flow-cytometry. Additionally, flow cytometry allows one to collect fluorescence data for a large population of cells. This eliminates variations and experimental artifacts that can be observed using techniques such as fluorescence imaging which only permit the examination of a small sample of cells. Cells were treated with nano-flares as described above (particle concentration, 10 nM). Molecular beacon probes (SEQ ID NO. 6 and SEQ ID NO. 7) were delivered to cells using Lipofectamine 2000 (Invitrogen). After treatment, cells were detached from culture flasks using trypsin. Flow cytometry was performed using a DakoCytomation CyAn, exciting at 635 nm.

20 **[0120]** Cell-lines transfected with nano-flares showed uniform single populations of fluorescent cells, consistent with the greater than 99% cell penetration that we observe when transfecting antisense particles (Rosi et al., Science 312: 1027-1030). Flow-cytometry revealed that SKBR3 cells treated with survivin nano-flares were highly fluorescent and 2.5 times more fluorescent than the population treated with non-complementary controls. For comparison, in C166 cell models, both probes resulted in a similar low fluorescent signal. These flow cytometry experiments are in excellent agreement with confocal imaging and demonstrate the uniform cellular internalization and intracellular signaling of the nano-flares.

25 **[0121]** Experiments then were designed to understand the unique properties of these probes in the context of intracellular detection experiments. First, the intracellular performance of nano-flares was compared with a molecular beacon reporter delivered using Lipofectamine, a commercial transfection agent (Peng et al., 2005, Cancer Res. 65: 1909-1917; Nitin et al., 2004, Nucleic Acids Res. 32: e58). Molecular beacons and nano-flares were introduced to SKBR3 cells (transfection concentration, 10 pM) and their signal abilities were studied using flow cytometry. Cells treated with survivin nano-flares produced 55 times greater fluorescence signal than those treated with survivin molecular beacon probes transfected at the same concentration. Fluorescence measurements outside of the cell culture indicate that each nano-flare probe contains approximately 10 fluorophores and therefore could be expected to potentially have a 10 times greater signal than the molecular beacon at equal probe concentrations. The larger than expected intracellular fluorescence suggests that nano-flares are internalized more rapidly or to a greater extent than the molecular beacon probes.

30 **[0122]** Next, molecular beacons were transfected at high concentration (0.5 nM) to achieve an intracellular fluorescence signal to that observed with the nano-flares. The background fluorescence contributed by the non-complementary probes was compared (both molecular beacon and nano-flare). The fluorescence of the non-complementary molecular beacon probe is significantly greater than that of the non-complementary nano-flare. Since the difference between the background and signal is critical for accurate target detection, the lower background of nano-flares provides an important advantage when detecting intracellular targets.

35 **[0123]** To probe how enzymatic degradation leads to non-specific signaling, nano-flares were incubated with the endonuclease DNase I (0.38 mg/L, a concentration significantly greater than what would be found in a cellular environment), and measured the rate of degradation by monitoring the increase in fluorescence signal as a function of time. Nano-flare probes were diluted to a concentration of 2.5 nM in PBS (pH 7.0), 0.25 mM MgCl₂ and 50 mg/L Bovine Serum Albumin (Fischer Scientific). Bovine Pancreatic DNase I (United States Biochemical) was added immediately before reading (concentration, 0.38 mg/L). All experiments were performed on a Photal Otsuka Electronics FluoDia T70 with excitation at 620 nm and emission at 665 nm. Molecular beacons were tested in an analogous manner at a concentration of 25 nM. The approximate rates of degradation under these experimental conditions were determined from the slope of the linear region of the degradation curves (Rizzo et al., 2002 Molecular and Cellular Probes 16: 277-283).

40 **[0124]** The results of the assay reveal that the nano-flare is degraded at a normalized rate of 0.275 nmol min⁻¹ under these conditions. In comparison, a molecular beacon is degraded at a normalized rate of 1.25 nmol min⁻¹, approximately 4.5 times more rapidly than the nano-flare. Since nuclease activity leads to increased background fluorescence in a

conventional probe, the reduced nuclease activity of the nano-flares leads to a system with lower background signal.

Example 6

5 **[0125]** To demonstrate an application where the cellular entry, elevated signaling, and low background of the nano-flare translate into a high sensitivity for changes in intracellular amounts of RNA, siRNA knockdown experiments were conducted to reduce the levels of survivin RNA transcripts in the SKBR3 cell models. siRNA against human survivin (Santa Cruz) was delivered to cells using Lipofectamine 2000 (Invitrogen) when cells were approximately 50% confluent (siRNA concentrations, 20, 40, and 80 nM). After 24 hours, the media was changed with media containing the nano-flare probes (particle concentration, 50 pM). After 6 hours, the cells were washed and fresh media was added. Cells were cultured for an additional 12 hours and analyzed using flow cytometry.

10 **[0126]** Cells were initially treated with siRNA against survivin, and the intracellular RNA levels were quantified using nano-flares and flow cytometry. An siRNA concentration-dependent shift in the fluorescence of the cell population was observed as a function of the concentration of siRNA added to the cell culture (Figure 3a). The siRNA concentration is given in the graph to the left of the histogram. In the untreated sample, half of the population exhibiting equal or greater fluorescence than the mean is shaded grey. Treated samples show a smaller fraction of the cell population exhibiting the mean fluorescence (declining grey, increasing black). To confirm that this shift was commensurate with a decrease in the number of survivin transcripts, RT-PCR measurements were conducted on samples treated with the same concentrations of siRNA. Cells were counted using a Guava EasyCyte Mini (Guava Technologies). Total RNA was isolated from the cell using an RNeasy Plus Kit (Qiagen) following the manufacturers protocol. During the cell lysis step, 5×10^7 copies of Enhanced Green Fluorescent Protein (EGFP) RNA were added to each sample to account for RNA loss during isolation and purification. To generate RNA standard curves for qRT-PCR, the fragments of RNA to be quantified were generated from the appropriate cellular RNA. Using PCR and primers containing a T7 promoter site, we converted the fragments into transcription compatible sequences (DNA \rightarrow RNA). The transcripts were purified using the MEGAclean kit (Ambion) following the manufacturer's protocol. RNA concentration was measured using the Ribogreen RNA quantification kit (Invitrogen), and a dilution series of stock RNA was used to generate a standard curve. Primers were:

30 **EGFP Forward** 5' -TCT TCT TCA AGG ACG ACG GCA ACT-3' (SEQ ID NO. 8)

35 **EGFP Reverse** 5' - TGT GGC GGA TCT TGA AGT TCA CCT -3' (SEQ ID NO. 9)

T7 EGFP Forward 5' -TGC ATA ATA CGA CTC ACT ATA GGG AGA TCT TCT TCA AGG ACG ACG GGC AAC T - 3' (SEQ ID NO. 10)

40 **Survivin Forward** 5'-ATG GGT GCC CCG ACG TTG- 3' (SEQ ID NO. 11)

Survivin Reverse 5' - AGA GGC CTC AAT CCA TGG - 3' (SEQ ID NO. 12)

45 **T7 Survivin Forward** 5' -TGC ATA ATA CGA CTC ACT ATA GGG AGA TGG GTG CCC CGA CGT TG-3' (SEQ ID NO. 13)

50 **[0127]** Quantitative-PCR and analysis were performed using LightCycler RNA master SYBR green kits (Roche Applied Sciences) according to the manufacturer's recommendation. Reverse transcription was allowed to proceed at 61°C for 20 minutes, followed by 45 amplification cycles (95°C, 5 sec; 54°C, 15 sec; 72°C, 20 sec), and target gene RNA was normalized to the standard curves generated. All reactions were done in triplicate.

55 **[0128]** The linear decrease in the fluorescence signal within the population of cells was in agreement with the decrease in the number of survivin RNA copies as determined by RT-PCR measurements (Figure 3b). Taken together, these results indicate that the nano-flares are sensitive to changes in the number of intracellular transcripts. The RT-PCR was conducted in triplicate, and the error bars shown above are the standard deviations of those measurements.

[0129] A new class of intracellular probe termed "nano-flares" has been developed. Nano-flares are novel and potentially very useful since they are the only probe that combines cellular transfection, enzymatic protection, RNA detection and quantification, and mRNA visualization. In addition to their demonstrated use in the context of siRNA knockdown

EP 2 121 987 B1

experiments, nano-flares are contemplated to be useful in other areas such as cell sorting, gene profiling, and real-time drug testing. Finally, given the ability of these materials to also act as gene regulation agents (Rosi et al., 2006, Science 312: 1027-1030; Seferos et al., 2007, ChemBioChem 8: 1230-1232), these probes are contemplated to easily adapted to simultaneously transfect, control and visualize gene expression in real-time.

5 **[0130]** In summary, these results demonstrate:

1) Gold nanoparticles assist in the intracellular delivery of a fluorophore-containing oligonucleotide that is capable of detecting a target.

10 2) These fluorescently labeled oligonucleotide-modified gold nanoparticle agents can be used to detect, visualize, and quantify intracellular targets.

3) The fluorescent signal that indicates the presence and quantity of specific mRNA targets can be transduced into a readable measure.

4) The efficient uptake of these agents, and their high signaling ability, and low toxicity makes them well suited for distinguishing cell populations.

15 5) The efficient uptake of these agents, and their high signaling ability surpasses conventional quencher-fluorophore oligonucleotide probes under the conditions studied.

6) The principles can be extended to other structure-switching recognition sequences such as nucleic acid aptamers and peptides.

20 **[0131]** The present invention contemplates that use of the probes will lead to the ability to simultaneously detect multiple intracellular targets, and quantify their intracellular concentrations in real-time. The principles are also contemplated to be applied to real-time monitoring of cell function in higher organisms, and used to concurrently deliver therapeutics while simultaneously monitoring their efficacy.

25 SEQUENCE LISTING

[0132]

30 <110> Mirkin, et al.

<120> Particles for Detecting Intracellular Targets

<130> 30938/27022R

35 <150> 60/900,648

<151> 2007-02-09

<160> 13

40 <170> PatentIn version 3.4

<210> 1

<211> 23

<212> DNA

45 <213> Artificial sequence

<220>

<223> Synthetic polynucleotide

50 <220>

<221> Misc_feature

<222> (23)..(23)

<223> nucleotide at position 23 is thiolated

55 <400> 1

cttgagaaag ggctgcaaaa aaa 23

<210> 2

EP 2 121 987 B1

<211> 10
<212> DNA
<213> Artificial sequence

5 <220>
<223> Synthetic polynucleotide

<220>
<221> Misc_feature
10 <222> (1)..(1)
<223> nucleotide at position 1 is tagged with Cy5

<400> 2
15 ttgcagccc 10

<210> 3
<211> 18 <212> DNA
<213> Artificial sequence

20 <220>
<223> Synthetic polynucleotide

<400> 3
25 tggcagccct ttctcaag 18

<210> 4
<211> 23
<212> DNA
<213> Artificial sequence

30 <220>
<223> Synthetic polynucleotide

<220>
35 <221> Misc_feature
<222> (23)..(23)
<223> nucleotide at position 23 is thiolated

<400> 4
40 ctatcgcgta caatctgcaa aaa 23

<210> 5
<211> 13
<212> DNA
45 <213> Artificial sequence

<220>
<223> Synthetic polynucleotide

50 <220>
<221> Misc_feature
<222> (1)..(1)
<223> nucleotide at position 1 is tagged with Cy5

55 <400> 5
tgcagattgt acg 13

<210> 6

<211> 24
 <212> DNA
 <213> Artificial sequence

5

<220>
 <223> Synthetic polynucleotide

<400> 6
 tcttctcaa ggacgacggc aact 24

10

<210> 7
 <211> 24
 <212> DNA
 <213> Artificial sequence

15

<220>
 <223> Synthetic polynucleotide

<400> 7
 tgtggcggat ctgaagttc acct 24

20

<210> 8
 <211> 24
 <212> DNA
 <213> Artificial sequence

25

<220>
 <223> Synthetic polynucleotide

<400> 8
 tcttctcaa ggacgacggc aact 24

30

<210> 9
 <211> 24
 <212> DNA
 <213> Artificial sequence

35

<220>
 <223> Synthetic polynucleotide

40

<400> 9
 tgtggcggat ctgaagttc acct 24

45

<210> 10
 <211> 52
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic polynucleotide

50

<400> 10
 tgcataatac gactcactat agggagatct tctcaagga cgacgggcaa ct 52

55

<210> 11
 <211> 18
 <212> DNA
 <213> Artificial sequence

<220>

<223> Synthetic polynucleotide

<400> 11

5 atgggtgccc cgacgttg 18

<210> 12

<211> 18

<212> DNA

10 <213> Artificial sequence

<220>

<223> Synthetic polynucleotide

<400> 12

15 agaggcctca atccatgg 18

<210> 13

<211> 44

<212> DNA

20 <213> Artificial sequence

<220>

<223> Synthetic polynucleotide

<400> 13

25 tgcataatac gactactat agggagatgg gtgccccgac gttg 44

30 **Claims**

1. Use of a nanoparticle in the production of a composition to determine intracellular concentration of a target molecule in vivo, wherein the nanoparticle comprises a binding moiety polynucleotide specific for said target molecule, said binding moiety polynucleotide labeled with a florescent marker,
 35 wherein when the target molecule is contacted intracellularly with the nanoparticle under conditions that allow association of the target molecule with the nanoparticle, the association of the target molecule and the nanoparticle results in detectable change in the marker proportional to the intracellular concentration of said target molecule.
2. An in vitro method of determining the intracellular concentration of a target molecule comprising the step of contacting
 40 the target molecule intracellularly with a nanoparticle under conditions that allow association of the target molecule with the nanoparticle, said nanoparticle comprising a binding moiety polynucleotide specific for said target molecule, said binding moiety polynucleotide labeled with a fluorescent marker, wherein the association of the target molecule and the nanoparticle results in detectable change in the marker, and wherein the change in the detectable marker is proportional to the intracellular concentration of said target molecule.
- 45 3. The use of claim 1 or the method of claim 2 wherein the binding moiety polynucleotide is DNA.
4. The use of claim 1 or the method of claim 2 wherein the binding moiety polynucleotide is RNA.
- 50 5. The use of claim 1 or the method of claim 2 wherein the target molecule is a polynucleotide.
6. The use of claim 1 or the method of claim 2 wherein said binding moiety polynucleotide is covalently attached to said nanoparticle and said marker is attached to a polynucleotide hybridized to said binding moiety polynucleotide, wherein association of said binding moiety polynucleotide with said target molecule releases said hybridized poly-
 55 nucleotide and said marker is detectable after release.
7. The use or the method of claim 6 wherein said marker attached to said polynucleotide is quenched when said polynucleotide with said marker is hybridized to said binding moiety polynucleotide.

8. The use of claim 1 or the method of claim 2 wherein said binding moiety polynucleotide comprises a marker which is a detectable label, wherein said marker is detectable only when said polynucleotide is associated with the target molecule.
- 5 9. The use or method of claim 8 wherein said marker is quenched when said binding moiety polynucleotide is not associated with said target molecule.
10. The use of claim 1 or method wherein said nanoparticle comprises a multiplicity of binding moiety polynucleotides.
- 10 11. The use or method of claim 10 wherein the binding moiety polynucleotides specifically associate with one target molecule.
12. The use or method of claim 10 wherein the binding moiety polynucleotides specifically associate with more than one target molecule.
- 15 13. The use or method of any of the preceding claims wherein the binding moiety polynucleotide is a nucleic acid aptamer.
14. The use or method of any of claims 1 through 4 or 6 through 13 wherein the target molecule is adenosine triphosphate (ATP).
- 20

Patentansprüche

- 25 1. Verwendung eines Nanopartikels bei der Herstellung einer Zusammensetzung zum Bestimmen der intrazellulären Konzentration eines Zielmoleküls in vivo, wobei das Nanopartikel ein für das Zielmolekül spezifisches Polynucleotid mit Bindungskomponente umfasst, wobei das Polynucleotid mit Bindungskomponente mit einem Fluoreszenzmarker markiert ist, wobei, wenn das Zielmolekül intrazellulär mit dem Nanopartikel unter Bedingungen in Kontakt gebracht wird, die die Assoziation des Zielmoleküls mit dem Nanopartikel erlauben, die Assoziation des Zielmoleküls und des Nanopartikels zu einer erfassbaren Veränderung des Markers führt, die zu der intrazellulären Konzentration des Zielmoleküls proportional ist.
- 30
- 35 2. In-vitro-Verfahren zur Bestimmung der intrazellulären Konzentration eines Zielmoleküls, umfassend die Stufe des intrazellulären Inkontaktbringens des Zielmoleküls mit einem Nanopartikel unter Bedingungen, die die Assoziation des Zielmoleküls mit dem Nanopartikel erlauben, wobei das Nanopartikel ein für das Zielmolekül spezifisches Polynucleotid mit Bindungskomponente umfasst, wobei das Polynucleotid mit Bindungskomponente mit einem Fluoreszenzmarker markiert ist, wobei die Assoziation des Zielmoleküls und des Nanopartikels zu einer erfassbaren Veränderung des Markers führt, und wobei die Veränderung des erfassbaren Markers zu der intrazellulären Konzentration des Zielmoleküls proportional ist.
- 40
3. Verwendung nach Anspruch 1 oder Verfahren nach Anspruch 2, wobei das Polynucleotid mit Bindungskomponente DNA ist.
- 45 4. Verwendung nach Anspruch 1 oder Verfahren nach Anspruch 2, wobei das Polynucleotid mit Bindungskomponente RNA ist.
5. Verwendung nach Anspruch 1 oder Verfahren nach Anspruch 2, wobei das Zielmolekül ein Polynucleotid ist.
- 50 6. Verwendung nach Anspruch 1, wobei das Polynucleotid mit Bindungskomponente an das Nanopartikel kovalent angehängt ist, und wobei der Marker an ein Polynucleotid angehängt ist, welches mit dem Polynucleotid mit Bindungskomponente hybridisiert ist, wobei die Assoziation des Polynucleotids mit Bindungskomponente mit dem Zielmolekül das hybridisierte Polynucleotid freisetzt und der Marker nach der Freisetzung erfassbar ist.
- 55 7. Verwendung oder Verfahren nach Anspruch 6, wobei der an das Polynucleotid angehängte Marker gelöscht wird, wenn das Polynucleotid mit dem Marker mit dem Polynucleotid mit Bindungskomponente hybridisiert wird.
8. Verwendung nach Anspruch 1 oder Verfahren nach Anspruch 2, wobei das Polynucleotid mit Bindungskomponente einen Marker umfasst, der eine erfassbare Markierung darstellt, wobei der Marker nur dann erfassbar ist, wenn das

Polynucleotid mit dem Zielmolekül assoziiert ist.

9. Verwendung oder Verfahren nach Anspruch 8, wobei der Marker gelöscht wird, wenn das Polynucleotid mit Bindungskomponente nicht mit dem Zielmolekül assoziiert ist.

5 10. Verwendung nach Anspruch 1 oder Verfahren nach Anspruch 2, wobei das Nanopartikel eine Vielzahl von Polynucleotiden mit Bindungskomponente umfasst.

10 11. Verwendung oder Verfahren nach Anspruch 10, wobei die Polynucleotide mit Bindungskomponente mit einem Zielmolekül spezifisch assoziieren.

12. Verwendung oder Verfahren nach Anspruch 10, wobei die Polynucleotide mit Bindungskomponente mit mehr als einem Zielmolekül spezifisch assoziieren.

15 13. Verwendung oder Verfahren nach einem der vorangehenden Ansprüche, wobei das Polynucleotid mit Bindungskomponente ein Nukleinsäureaptamer ist.

20 14. Verwendung oder Verfahren nach einem der Ansprüche 1 bis 4 oder 6 bis 13, wobei das Zielmolekül Adenosintriphosphat (ATP) ist.

Revendications

25 1. Utilisation d'une nanoparticule dans la production d'une composition pour déterminer la concentration intracellulaire d'une molécule cible in vivo, où la nanoparticule comprend un polynucléotide à groupement de liaison spécifique pour ladite molécule cible, ledit polynucléotide à groupement de liaison marqué avec un marqueur fluorescent, où, quand la molécule cible est mise en contact de manière intracellulaire avec la nanoparticule dans des conditions qui permettent une association de la molécule cible avec la nanoparticule, l'association de la molécule cible et de la nanoparticule conduit à un changement détectable dans le marqueur proportionnel à la concentration intracellulaire de ladite molécule cible.

35 2. Procédé de détermination de la concentration intracellulaire d'une molécule cible comprenant l'étape de mise en contact de la molécule cible de manière intracellulaire avec une nanoparticule dans des conditions qui permettent une association de la molécule cible avec la nanoparticule, ladite nanoparticule comprenant un polynucléotide à groupement de liaison spécifique pour ladite molécule cible, ledit polynucléotide à groupement de liaison marqué avec un marqueur fluorescent, où l'association de la molécule cible et de la nanoparticule conduit à un changement détectable dans le marqueur, et où le changement dans le marqueur détectable est proportionnel à la concentration intracellulaire de ladite molécule cible.

40 3. Utilisation selon la revendication 1 ou procédé selon la revendication 2 où le polynucléotide à groupement de liaison est un ADN.

45 4. Utilisation selon la revendication 1 ou procédé selon la revendication 2 où le polynucléotide à groupement de liaison est un ARN.

5. Utilisation selon la revendication 1 ou procédé selon la revendication 2 où la molécule cible est un polynucléotide.

50 6. Utilisation selon la revendication 1 ou procédé selon la revendication 2 où ledit polynucléotide à groupement de liaison est lié de manière covalente à ladite nanoparticule et ledit marqueur est lié à un polynucléotide hybridé audit polynucléotide à groupement de liaison, où l'association dudit polynucléotide à groupement de liaison avec ladite molécule cible libère ledit polynucléotide hybridé et ledit marqueur est détectable après la libération.

55 7. Utilisation ou procédé selon la revendication 6 où ledit marqueur lié audit polynucléotide est éteint quand ledit polynucléotide avec ledit marqueur est hybridé audit polynucléotide à groupement de liaison.

8. Utilisation selon la revendication 1 ou procédé selon la revendication 2 où ledit polynucléotide à groupement de liaison comprend un marqueur qui est un marqueur détectable, où ledit marqueur est détectable seulement quand ledit polynucléotide est associé avec la molécule cible.

EP 2 121 987 B1

9. Utilisation ou procédé selon la revendication 8 où ledit marqueur est éteint quand ledit polynucléotide à groupement de liaison n'est pas associé avec ladite molécule cible.

5 10. Utilisation selon la revendication 1 ou procédé selon la revendication 2 où ladite nanoparticule comprend une multiplicité de polynucléotides à groupement de liaison.

11. Utilisation ou procédé selon la revendication 10 où les polynucléotides à groupement de liaison s'associent spécifiquement avec une molécule cible.

10 12. Utilisation ou procédé selon la revendication 10 où les polynucléotides à groupement de liaison s'associent spécifiquement avec plus d'une molécule cible.

13. Utilisation ou procédé selon l'une quelconque des revendications précédentes où le polynucléotide à groupement de liaison est un aptamère d'acide nucléique.

15 14. Utilisation ou procédé selon l'une quelconque des revendications 1 à 4 ou 6 à 13 où la molécule cible est l'adénosine triphosphate (ATP).

20

25

30

35

40

45

50

55

Figure 1




Figure 2





Figure 3



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 2006183247 A [0008]
- US 3687808 A [0040] [0049] [0051]
- US 4469863 A [0040]
- US 4476301 A [0040]
- US 5023243 A [0040]
- US 5177196 A [0040]
- US 5188897 A [0040]
- US 5264423 A [0040]
- US 5276019 A [0040]
- US 5278302 A [0040]
- US 5286717 A [0040]
- US 5321131 A [0040]
- US 5399676 A [0040]
- US 5405939 A [0040]
- US 5453496 A [0040]
- US 5455233 A [0040]
- US 5466677 A [0040] [0041]
- US 5476925 A [0040]
- US 5519126 A [0040]
- US 5536821 A [0040]
- US 5541306 A [0040]
- US 5550111 A [0040]
- US 5563253 A [0040]
- US 5571799 A [0040]
- US 5587361 A [0040]
- US 5194599 A [0040]
- US 5565555 A [0040]
- US 5527899 A [0040]
- US 5721218 A [0040]
- US 5672697 A [0040]
- US 5625050 A [0040]
- US 5034506 A [0041] [0043]
- US 5166315 A [0041]
- US 5185444 A [0041]
- US 5214134 A [0041]
- US 5216141 A [0041]
- US 5235033 A [0041]
- US 5264562 A [0041]
- US 5264564 A [0041]
- US 5405938 A [0041]
- US 5434257 A [0041]
- US 5470967 A [0041]
- US 5489677 A [0041] [0043]
- US 5541307 A [0041]
- US 5561225 A [0041]
- US 5596086 A [0041]
- US 5602240 A [0041] [0043]
- US 5610289 A [0041]
- US 5608046 A [0041]
- US 5618704 A [0041]
- US 5623070 A [0041]
- US 5663312 A [0041]
- US 5633360 A [0041]
- US 5677437 A [0041]
- US 5792608 A [0041]
- US 5646269 A [0041]
- US 5677439 A [0041]
- US 5539082 A [0042]
- US 5714331 A [0042]
- US 5719262 A [0042]
- US 20040219565 A [0045]
- US 4981957 A [0047]
- US 5118800 A [0047]
- US 5319080 A [0047]
- US 5359044 A [0047]
- US 5393878 A [0047]
- US 5446137 A [0047]
- US 5466786 A [0047]
- US 5514785 A [0047]
- US 5519134 A [0047]
- US 5567811 A [0047]
- US 5576427 A [0047]
- US 5591722 A [0047]
- US 5597909 A [0047]
- US 5610300 A [0047]
- US 5627053 A [0047]
- US 5639873 A [0047]
- US 5646265 A [0047]
- US 5658873 A [0047]
- US 5670633 A [0047]
- US 5792747 A [0047]
- US 5700920 A [0047]
- WO 9839352 A [0048]
- WO 9914226 A [0048]
- US 4845205 A [0049]
- US 5130302 A [0049]
- US 5134066 A [0049]
- US 5175273 A [0049]
- US 5367066 A [0049]
- US 5432272 A [0049] [0051]
- US 5457187 A [0049]
- US 5459255 A [0049]
- US 5484908 A [0049]
- US 5502177 A [0049]
- US 5525711 A [0049]
- US 5552540 A [0049]
- US 5587469 A [0049]
- US 5594121 A [0049]

- US 5596091 A [0049]
- US 5614617 A [0049]
- US 5645985 A [0049]
- US 5830653 A [0049]
- US 5763588 A [0049]
- US 6005096 A [0049]
- US 5750692 A [0049]
- US 5681941 A [0049]
- EP 1072679 A [0050]
- WO 9712896 A [0050]
- WO 1999011655 A [0056]
- WO 1998047343 A [0056]
- US 6844161 B [0056]
- US 6403312 B [0056]
- US 20030147966 A [0067] [0071] [0072]
- US 03445102 A [0068]
- US 0150825 W [0068]
- US 4489055 A [0069]
- US 5472881 A [0076]
- US 34466799 A [0076]
- US 09603830 B [0076]
- US 09760500 B [0076]
- US 09820279 B [0076]
- US 09927777 B [0076]
- US 9712783 W [0076]
- US 0017507 W [0076]
- US 0101190 W [0076]
- US 0110071 W [0076]
- US 60900648 B [0132]

Non-patent literature cited in the description

- **ELGHANIAN et al.** *Science*, 1997, vol. 277, 1078-1081 [0004]
- **NAM et al.** *Science*, 2003, vol. 308, 1884-1886 [0004]
- **MIRKIN et al.** *Nature*, 1996, vol. 382, 607-609 [0004] [0112]
- **ALIVISATOS et al.** *Nature*, 1996, vol. 382, 609-611 [0004]
- **DEMERS et al.** *Angew. Chem. Int. Ed.*, 2003, vol. 40, 3071-3073 [0004]
- **ROSI et al.** *Science*, 2006, vol. 312, 1027-1030 [0004] [0032] [0129]
- **SANDHU et al.** *Bioconjugate Chem.*, 2002, vol. 13, 3-6 [0004]
- **TKACHENKO et al.** *J. Am. Chem. Soc.*, 2003, vol. 125, 4700-4701 [0004]
- **LYTTON-JEAN ; MIRKIN.** *J. Am. Chem. Soc.*, 2005, vol. 127, 12754-12755 [0004]
- **SEFEROS et al.** *ChemBioChem*, 2007, vol. 8, 1230-1232 [0004] [0129]
- **FEMINO et al.** *Science*, 1998, vol. 280, 585-590 [0007]
- **KLOOSTERMAN et al.** *Nat. Methods*, 2006, vol. 3, 27-29 [0007]
- **TYAGI et al.** *Nat. Biotechnol.*, 1996, vol. 14, 303-308 [0007]
- **SOKOL et al.** *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 11538-11543 [0007]
- **PENG et al.** *Cancer Res.*, 2005, vol. 65, 1909-1917 [0007] [0116] [0121]
- **PERLETTE et al.** *Anal. Chem.*, 2001, vol. 73, 5544-5550 [0007]
- **NITIN et al.** *Nucleic Acids Res.*, 2004, vol. 32, e58 [0007] [0121]
- **SANTANGELO et al.** *Nucleic Acids Res.*, 2004, vol. 32, e57 [0007]
- **BRATU et al.** *Proc. Natl. Acad. Sci. USA*, 2003, vol. 100, 13308-13313 [0007]
- **SANTANGELO et al.** *Annals of Biomedical Engineering*. 2006, vol. 34, 39-50 [0007]
- **ZABNER et al.** *J. Bio. Chem.*, 1995, vol. 270, 18997-19007 [0007]
- **KUKOWSKA-LATALLO et al.** *Proc. Natl. Acad. Sci. USA*, 1996, vol. 93, 4897-4902 [0007] [0069]
- **OPALINSKA ; GEWIRTZ.** *Nat. Rev. Drug Disc.*, 2002, vol. 1, 503-514 [0007]
- **LI et al.** *Nucleic Acids Res.*, 2004, vol. 28, e52 [0007]
- **RIZZO et al.** *Molecular and Cellular Probes*, 2002, vol. 16, 277-283 [0007] [0123]
- **ZHANG et al.** *Nature Materials*, 2005, vol. 4, 826-831 [0008]
- **DUBERTRET et al.** *Nature Biotechnology*, 2001, vol. 19, 365-370 [0008]
- **MAXWELL et al.** *J. Am. Chem. Soc.*, 2002, vol. 124 (32), 9606-9612 [0008]
- **DUBERTRET et al.** *Nat. Biotechnol.*, 2001, vol. 19, 365-370 [0032] [0095]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual*. 1989 [0037]
- *Oligonucleotides and Analogues*. Oxford University Press, 1991 [0037]
- **NIELSEN et al.** *Science*, 1991, vol. 254, 1497-1500 [0042]
- **MESMAEKER.** *Current Opinion in Structural Biology*, 1995, vol. 5, 343-355 [0044]
- **SUSAN M. FREIER ; KARL-HEINZ ALTMANN.** *Nucleic Acids Research*, 1997, vol. 25, 4429-4443 [0044] [0051]
- **MARTIN et al.** *Helv. Chim. Acta*, 1995, vol. 78, 486-504 [0046]
- *The Concise Encyclopedia Of Polymer Science And Engineering*. John Wiley & Sons, 1990, 858-859 [0049]
- **ENGLISCH et al.** *Angewandte Chemie, International Edition*, 1991, vol. 30, 613 [0049]
- **SANGHVI, Y. S.** *Antisense Research and Applications*. CRC Press, 1993, 289-302 [0049]

- **SANGHVI.** Antisense Research and Application. CRC Press, 1993 [0051]
- **ENGLISCH et al.** *Angewandte Chemie*, 1991, vol. 30, 613-722 [0051]
- Concise Encyclopedia of Polymer Science and Engineering. John Wiley & Sons, 1990, 858-859 [0051]
- **COOK.** *AntiCancer Drug Design*, 1991, vol. 6, 585-607 [0051]
- Combinatorial Peptide and Nonpeptide Libraries: A Handbook [0055]
- **DEVLIN et al.** *Science*, 1990, vol. 249 (4967), 404-406 [0055]
- **MATSUURA et al.** *Protein Science*, 2002, vol. 11, 2631-2643 [0056]
- **OHUCHI et al.** *Nucleic Acids Res.*, 01 October 1998, vol. 26 (19), 4339-4346 [0056]
- **CHRISEY et al.** *Nucleic Acids Research*, 1996, vol. 24, 3031-3039 [0064]
- **CHARREYRE et al.** *Langmuir*, 1997, vol. 13, 3103-3110 [0064]
- **FAHY et al.** *Nucleic Acids Research*, 1993, vol. 21, 1819-1826 [0064]
- **ELAISSARI et al.** *J. Colloid Interface Sci.*, 1998, vol. 202, 251-260 [0064]
- **KOLAROVA et al.** *Biotechniques*, 1996, vol. 20, 196-198 [0064]
- **WOLF et al.** *Nucleic Acids Research*, 1987, vol. 15, 2911-2926 [0064]
- Clusters and Colloids. VCH, 1994 [0069]
- Colloidal Gold: Principles, Methods, and Applications. Academic Press, 1991 [0069]
- **MASSART, R.** *IEEE Transactions On Magnetics*, 1981, vol. 17, 1247 [0069]
- **AHMADI, T. S. et al.** *Science*, 1996, vol. 272, 1924 [0069]
- **HENGLEIN, A. et al.** *J. Phys. Chem.*, 1995, vol. 99, 14129 [0069]
- **CURTIS, A. C. et al.** *Angew. Chem. Int. Ed. Engl.*, 1988, vol. 27, 1530 [0069]
- **FATTAL et al.** *J. Controlled Release*, 1998, vol. 53, 137-143 [0069]
- **LIU et al.** *J. Am. Chem. Soc.*, 2004, vol. 126, 7422-7423 [0069]
- **TONDELLI et al.** *Nucl. Acids Res.*, 1998, vol. 26, 5425-5431 [0069]
- **HAVASHI.** *Vac. Sci. Technol.*, July 1987, vol. A5 (4), 1375-84 [0071]
- **HAYASHI.** *Physics Today*, December 1987, 44-60 [0071]
- MRS Bulletin. December 1987, 16-47 [0071]
- **MARINAKOS et al.** *Adv. Mater.*, 1999, vol. 11, 34-37 [0072]
- **MARINAKOS et al.** *Chem. Mater.*, 1998, vol. 10, 1214-19 [0072]
- **ENUSTUN ; TURKEVICH.** *J. Am. Chem. Soc.*, 1963, vol. 85, 3317 [0072]
- **WHITESIDES.** *Proceedings of the Robert A. Welch Foundation 39th Conference On Chemical Research Nanophase Chemistry*, 1995, 109-121 [0076]
- **MUCIC et al.** *Chem. Commun.*, 1996, 555-557 [0076]
- **BURWELL.** *Chemical Technology*, 1974, vol. 4, 370-377 [0076]
- **MATTEUCCI ; CARUTHERS.** *J. Am. Chem. Soc.*, 1981, vol. 103, 3185-3191 [0076]
- **GRABAR et al.** *Anal. Chem.*, 1995, vol. 67, 735-743 [0076]
- **NUZZO et al.** *J. Am. Chem. Soc.*, 1987, vol. 109, 2358 [0076]
- **ALLARA ; NUZZO.** *Langmuir*, 1985, vol. 1, 45 [0076]
- **ALLARA ; TOMPKINS.** *J. Colloid Interface Sci.*, 1974, vol. 49, 410-421 [0076]
- **ILER.** *The Chemistry Of Silica.* Wiley, 1979 [0076]
- **TIMMONS ; ZISMAN.** *J. Phys. Chem.*, 1965, vol. 69, 984-990 [0076]
- **SORIAGA ; HUBBARD.** *J. Am. Chem. Soc.*, 1982, vol. 104, 3937 [0076]
- **HUBBARD.** *Acc. Chem. Res.*, 1980, vol. 13, 177 [0076]
- **HICKMAN et al.** *J. Am. Chem. Soc.*, 1989, vol. 111, 7271 [0076]
- **MAOZ ; SAGIV.** *Langmuir*, 1987, vol. 3, 1045 [0076]
- **MAOZ ; SAGIV.** *Langmuir*, 1987, vol. 3, 1034 [0076]
- **WASSERMAN et al.** *Langmuir*, 1989, vol. 5, 1074 [0076]
- **ELTEKOVA ; ELTEKOV.** *Langmuir*, 1987, vol. 3, 951 [0076]
- **LEC et al.** *J. Phys. Chem.*, 1988, vol. 92, 2597 [0076]
- **ALTSCHUL et al.** *J. Mol. Biol.*, 1990, vol. 215, 403-410 [0085]
- **ZHANG ; MADDEN.** *Genome Res.*, 1997, vol. 7, 649-656 [0085]
- **DULKEITH et al.** *Nano Lett.*, 2005, vol. 5, 585-589 [0095]
- **LOVE et al.** *Chem. Rev.*, 2005, vol. 105, 1103-1169 [0100] [0113]
- **FRENS, G.** *Nature-Physical Science*, 1973, vol. 241, 20-22 [0113]
- **ALTIERI et al.** *Oncogene*, 2003, vol. 22, 8581-8589 [0116]
- **ROSI et al.** *Science*, vol. 312, 1027-1030 [0120]